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CNS, Central Nervous System
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VAS, Visual Analog Scale
Vd, Volume of Distribution
VMAT-2, Vesicular Monoamine Transporter
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3,4-methylenedioxymethamphetamine (MDMA, ecstasy) is a substituted
amphetamine, used for its euphoric effects. Its use reached its zenith in the mid
to late 1990's, but it is still widely abused today, especially among the youth.
MDMA is one of the most intensely studied drugs of abuse and although there is
a growing consensus that MDMA is toxic to humans, the mechanisms underlying
its toxic effects remain to be elucidated. Among the theories for the acute and
neurotoxic effects of MDMA, clinical and experimental data from animal models
support the view that systemic metabolism contributes significantly to toxicity1. As
with any drug of abuse, MDMA research is highly politicised. Its eventual
prohibition in the 1980's was contested by certain sectors in psychotherapy, while
on the other hand, it is still subjected to regular demonization in the popular
press. Hence, MDMA as a substance which causes a complex pharmacological
response still deserves objective investigation.
In vitro evidence has suggested that cytochrome P450 isoform 2D6 (CYP2D6),
the enzyme that contributes to MDMA phase I metabolism, is itself inhibited by
MDMA2. This mechanism-based inhibition of the enzyme, leads to a quasi
irreversible inactivation whose activity recovers with newly synthesised enzyme
and is independent of MDMA pharmacokinetics. This was further studied in vivo
in a clinical trial designed to study the pharmacology of two consecutive doses of
MDMA3. It was seen in this study that CYP2D6 contributed 30% towards MDMA
metabolism. Considering MDMA acute toxic effects, it would therefore be prudent
to study the duration of inhibition of CYP2D6 by MDMA to allow an estimate of
the incurred risk by MDMA users of experiencing pharmacological interactions
with substrates of the same enzyme that may endanger their lives.
MDMA is both O-demethylenated and N-demethylated by CYP2D6, CYP1A2,
CYP3A4 and another cytochrome P450 isoform, CYP2B6. These P450 systems
demonstrate differing affinities for the substrate and differ in their contribution to
O-demethylenation and N-demethylation. The contributions of these and possible
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Justification
changes in the activities of these enzymes following MDMA administration have
never been studied in vivo.
Furthermore, the CYP2D6 gene is highly polymorphic with some alíeles coding
for a completely inactive protein and others for proteins of lower activity and
different substrate affinities. Following the fortunate inclusion of a CYP2D6 poor
metabolizer in a clinical trial studying two repeated doses of MDMA, data were
reanalysed according to CYP2D6 genotype and it was observed that possession
of CYP2D6*4 alíele affects MDMA pharmacology4. Thus, any study of CYP2D6
substrate metabolism must take into account the interindividual differences in its
activity caused by genetic polymorphisms.
Although there is much evidence in animals and humans suggesting MDMA to be
a serotonergic neurotoxin, there is still much debate as to what is the cause of
these long-term changes. Research points towards the excessive production of
reactive oxygen species (ROS) in the brain following MDMA administration5.
MDMA induces hyperthermia, excessive cerebral dopamine release and leads
dysregulation of energy metabolism6"10. Furthermore, the metabolism of MDMA
leads to the production of a reactive catechol, products of which have been found
to cause serotonergic neurotoxicity in rats11. The source of this excessive ROS
production and consequent long-term serotonergic changes could be caused by
any of these different pharmacological factors. Animal models, especially rats
have been used for many years to study these sequelae. Consequently, it would
be interesting to potentiate neurotoxicity by interfering in MDMA and dopamine
metabolism and by changing body temperature to investigate which of these
previously mentioned factors hold more importance in the development of long-






Designer drugs are synthesised by chemically modifying the structure of already
known natural products or medical drugs resulting in similar if not heightened
pharmacological effects of the precursor. The synthesis of designer drugs is
usually relatively simple, since their production is carried out in a clandestine
setting with limited resources. They are frequently sold in the form of pills of
various colours and imprinted with a variety of designs to target their sale towards
a current illegal drugs market. In function of their chemical structure, designer
drugs can be divided into five categories: phenylethylamines, synthetic opiates,
arylhexylamines, derivatives of methaqualone and others.
1.1.1. A brief history of MDMA
3,4-Methylenedioxymethamphetamine (MDMA, "ecstasy") is a phenylethylamine
structurally similar to amphetamine and mescaline. Other structurally similar
methylenedioxy compounds are also found as aromatic constituents of oils and
spices. Some more commonly mentioned examples are safrole, piperine and
myristicin which are found in sassafras, nutmeg and pepper, respectively (Figure
1.1). MDMA was first synthesised in 1912 by Merck and first patented in 1914
(patent n° 274.350) as an anorexic. The first reported study was in animals in
1953 by the U.S. Army. In 1965 Alexander Shulgin synthesised the compound
once again, during his investigations into new psychoactive compounds deriving
from the essential oils of nutmeg12. In many ways, he and his contemporaries can
be credited with the introduction of its use in psychotropic therapy in the 1960's
and 1970's. Its properties were considered useful by psychotherapists due to its
induction of feelings of euphoria, friendliness, closeness to others, and empathy
after its administration. Although MDMA shares properties with both
hallucinogens and stimulants it has been classed as an "entactogen" by some
authors13. The recreational use of MDMA began in the late 1970's leading to it
25
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being classed as a controlled substance in the UK in 1977. However, use
continued during the 1980's and in 1984 the World Health Organisation (WHO)
recommended that MDMA be included in a list of substances with a high abuse
potential leading the way for a decision of the North American Drug Enforcement
Administration to include it on the Schedule I of illegal substances (those with a
high potential of abuse with a lack of medical application). Finally, in 1986 and
after some debate between authorities and psychotherapists, MDMA was
considered internationally illegal by the WHO Special Committee on Drug
Dependencies14. In Spain, approximately one month following the announcement
by the WHO, the use, fabrication, importation, transportation and sale of MDMA
was prohibited by ministerial order in the Boletín Oficial del Estado. Its prohibition
did not stop its increase in use in Europe and North America in the 1990's. It is
primarily consumed by young people in large dance and music environments
("raves") and to a lesser extent in smaller social settings15. Until the middle of the
1990's it was not possible to conduct clinical studies with MDMA. Currently, the
countries where such studies can be carried out are the USA (by authorisation of
the FDA), Switzerland, Great Britain and Spain. In Germany it is also authorised
















Figure 1.1. Amphetamine, common substituted amphetamines and naturally occurring
compounds structurally related to MDMA. MDA = 3,4-methylenedioxyamphetamine;
MDMA = 3,4-methylenedioxymethamphetamine; MDEA = 3,4-
methylenedioxyethylamphetamme; PMA = paramethoxyamphetamine; TMA = 2,4,5-
trimehtoxyamphetamine; DOB = 4-bromo-2,5-dimethoxyamphetamine; DOM = 4-methyl-
2,5-dimethoxymethamphetamine; 2CB = 4-bromo-2,5-dimethoxymethamphetamine.
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1.2. Epidemiology of MDMA use
1.2.1. Prevalence and patterns of use
In the latest report from the European Monitoring Centre for Drugs and Drug
Addiction16, ecstasy has been tried by 0.2-7.1% of all adults (average 2.6%). Half
of the countries report total adult life-time prevalence rates of 1.8% or lower, with
the highest prevalence rates being reported by the Czech Republic (7.1%) and
the United Kingdom (6.7%). The prevalence of last year use of ecstasy ranges
from 0.2% to 3.5%, but half of the countries report prevalence rates of 0.5% or
below. It has been estimated that almost 8.5 million Europeans have tried
ecstasy, and almost 3 million have used it in the last year. Among young adults
across the European countries, the prevalence of lifetime use of ecstasy is 5.2%,
ranging from 0.5% to 14.6%, although rates of less than 3.6% are reported by
half of the countries. The Czech Republic (14.6%), the United Kingdom (12.7%)
and Spain (8.3%) report the highest prevalence rates. Ecstasy use is
predominantly a youth phenomenon. In the 15-24 years age group, lifetime use
ranges from 0.4% to 18.7%, with the highest figures reported by the Czech
Republic (18.7%) and the United Kingdom (10.7%), with higher rates among
males (0.3-23.2%) than among females (0.4-13.9%). Use in the last year ranges
from 0.3% to 12%, with the Czech Republic (12%) and Estonia (6.1%) reporting
the highest figures. Last month prevalence rates lower than 3% are reported by
seven countries. Prevalence rates are typically higher in urban areas, and in
particular among people frequenting discos, clubs or dancing events. Among 15
to 16-year-old school students, surveys show that overall lifetime prevalence of
ecstasy use increased over the period 1995-2003, with the greatest increases
occurring in the Czech Republic and most of the new EU Member States. Even
though its use may be still increasing among young people, its escalation among
the general population seems to be limited, at least for the time being.
28
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For comparison, the 2006 United States National Survey on Drug Use and Health
reports that lifetime experience of ecstasy use among adults (defined as 12 years
and older) rose from 4.3% in 2002 to 5.0% in 2006. However, recent use of
ecstasy (last 12 months) decreased from 1.3% to 0.9% in the same period. Males
and females had similar rates of past month use of ecstasy (0.2 percent for both).
Among persons aged 12 to 49, the average age at first use was 20.6 years17.
MDMA users are known to on average take more than one pill per session, with
doses averaging from 1.8 to 2.9 per session reaching a maximum of 6.56
depending on the type of user18. It has also been documented that users may
"binge" on ecstasy19. Solowij et al., observed in a group of 100 individuals that
15% had at some time used ecstasy for a few days in a row20. It was later
reported by same research group that heaviest users can take up to 30 pills in
one session, with 35% admitting that they had binged on ecstasy in the
preceding 6 months21. In the UK, heavy users may binge with some 15-25 pills
per session22. A report from users in Scotland referred to two distinct activities.
First "stacking", which is taking several doses at once, and second "boosting",
which is taking several tablets but at intervals over a period of time. During a
binge, users may both stack and boost. In this study 39% of the users admitted
that they binged for 1-2 days, with 38% admitting that they would binge again23.
Demands for treatment related to ecstasy use are reported to account for less
than 1% of all treatment demands in most countries, with the exception of
Cyprus, Hungary, Ireland and Turkey, where ecstasy clients constitute between
4% and 6% of all clients seeking treatment for drug dependence. The number of
deaths associated with MDMA consumption is relatively low when compared to
the large population exposed to this substance. However, the frequency of
recorded incidents associated with its acute toxicity is high. In the United States,
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Figure 1.2. Last year prevalence of ecstasy use in young adults (15-34). Source: The State
of the Drugs Problem in Europe, 2006 report, EMCDDA, p 53
1.2.2. MDMA use in Spain
In a recently presented school survey about drugs, which was conducted in 2006,
26.454 youths between 14 and 18 years participated, 3.3% of the interviewees
admitted that they had taken ecstasy at least once, 2.4% in the last year and
1.4% in the last month (Observatorio Español sobre las Drogas, PNSD, Madrid,
Informe de la Encuesta Estatal Sobre Uso de Drogas en Estudiantes de
Enseñanzas Secundarias (ESTUDES) 2006-2007,
http://www.pnsd.msc.es/Categoria2/observa/pdf/Estudes2006-2007.pdf). These
data compared to those of previous years show a decrease in consumption. The
prevalence of consumption was found to be greater in males than it is in females.
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In the home survey concerning drugs conducted in 2006, 27.934 people
participated between the ages of 15 and 64, 4.4% of the interviewees recalled
that they had taken ecstasy at least once, 1.2% in the last year and 0.6% in the
last month (Plan Nacional sobre Drogas). Those that consumed cocaine and
cannabis in the last year also reported the similtaneous of ecstasy: cannabis
(9.1%), cocaine (27.5%). The average age of initial consumption in this
population was 20.1 years.
In a report conducted by the Plan Nacional Sobre Drogas in 199725, various data
were presented concerning the development and extent of use of MDMA in
universities and secondary schools in Spain in the previous years. A revision was
done of the existing epidemiological data and results were presented of a survey
carried out by the investigating authors of the report of 418 consumers of pills in
five Spanish Autonomous Communities (Madrid, Valencia, Andalucía, Murcia,
and Baleares). Among the most noticeable sociodemographic factors reported
was that two thirds of the interviewed consumers were male. The average age of
the sample was 21.9 years, with a range of ages between 18 and 53 years, but
the majority of consumers comprised of those between the ages of 18 and 24.
The educational and social levels of those surveyed varied; the majority (35%)
being students, followed by waiters and people who worked in restaurants and
clubs. It was also pointed out that a large majority of people took the substance in
the company of other people or with a partner, while only 4% of consumers took it
alone. The drug was found to be used at parties or discos by nearly 80% of those
surveyed. Some 32% were experimental or occasional consumers (between 10
and 49 times in their lives), up to 24% said they had used these types of
substances less than 9 times, while only 14% admitted using the drug more than
100 times. On the other hand, 76% consumed ecstasy and alcohol
simultaneously. The simultaneous use of cannabis (76%), other amphetamines
(34%) or LSD (33%) was also reported. Finally it was pointed that those who
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used the drug had a decreased ability to drive a vehicle while under its influence.
The results of this survey seemed to demonstrate that these substances are
frequently used along with alcohol, although the percentages could vary
according to the sample. This seems to contradict the opinion that users only
drink water while taking the drug. Another noticeable result was the dose taken
and the intervals between distinct doses. It seems that users in this study also
admitted taking one or more dose of ecstasy per session. A considerable
percentage of the subjects took an initial dose (half or one whole pill) and then
another dose between thirty minutes and two hours later (a half pill). Although
some subjects only take one dose, more than two doses are frequently taken,
including as many as six in one session. The average is 1.5 to 2.5 pills of ecstasy
per session or party, with 25% of the users taking more than 4 pills.
Ecstasy is sold as the racemate or mixture of the enantiomers (R)-MDMA and
(S)-MDMA. The content of ecstasy pills varies, but the proportion of falsifications
is relatively low, more than half contain MDMA, 30% contain other analogous
phenylethylamines (MDE, MDA), the rest contain other psychostimulants
(amphetamine or caffeine) or substances without psychoactive effects. The
average MDMA content of a pill is 80 mg, ranging between 40 and 200 mg. On
occasions pills can contain hallucinogenic and other more dangerous substances
(e.g. paramethoxyamphetamine or PMA)26.
1.3. The pharmacology of MDMA
As occurs with the majority of drugs of abuse, some of the pharmacological
effects of MDMA are directly sought by users (euphoria, well-being) and others
are clearly unwanted effects and moreover are manifestations of intoxication.
MDMA and other designer drugs produce euphoria and psychostimulation,
increase empathy and alter levels of perception. The sought effect is euphoria,
the sensation of well-being and pleasure, along with the psychostimulant effects
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of an increase in energy, talkativeness, decrease in tiredness and appetite. Users
refer to an induction of a positive emotional state and pleasure, characterised by
an increase in empathy. Tendencies to be intimate with those around them, a
greater facility for communication and for interpersonal relation, are those
referred to as entactogenic effects. MDMA is not an aphrodisiac although it
appears to increase sensuality. In comparison with amphetamine it does not
improve psychomotor performance or concentration, and can even worsen it at
high doses. Regarding some of the perceptive effects, the most frequent are a
certain amount of sensory hypersensitivity (frequently of a tactile nature), an
alteration in the visual chromatics with changes in the intensity of colours,
alterations in the subjective perception of time and a greater auditory sharpness.
MDMA and its derivatives are not hallucinogenic substances, although
descriptions do exist in cases of intoxication and when it is administered at high
doses. Some of the derived hallucinogens like DOB, DOM, TMA, or PMA
produce hallucinations at lower doses. When the euphoric effects diminish,
sensations of intense relapse including fatigue and disinterest are felt. Many
subjects pass the entire week in this dysphoric state until they take the drug
again the following weekend27.
MDMA and other designer drugs produce a stimulation of the sympathetic
nervous system with an increase in the pupil diameter (mydriasis), which may
cause blurred vision and greater sensitivity to light. They also produce dry mouth,
sweating, trembling, tension in the jaw (trismus), chewing movements and
grinding of the teeth (bruxism), and a slight increase in body temperature. They
increase arterial pressure and heart rate (palpitations and tachycardia). The
majority of these effects are considered by users to be unwanted 27.
It has been reported that MDMA can increase the plasma concentrations of
prolactin, cortisol and ACTH, and vasopressin (antidiuretic hormone)28. It seems
that following a single dose of MDMA a reversible immunosuppression is
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produced (a reduction in CD4+ T cell concentration) but may last some days
following repetitive dosing29. In chronic users a higher risk of contracting
infectious disease has been reported30. It is not clear the effects MDMA has on
pregnancy. There are citings of increases in the incidences of malformations but
contradictory data also exist31.
1.3.1. MDMA pharmacodynamics
The mechanism of action of MDMA and its derivatives are similar to
amphetamine, causing the release of the monoamines norepinephrine, dopamine
and serotonin into the synaptic cleft. The difference is that while amphetamine
has more dopaminergic and adrenergic activities than serotonergic, MDMA and
other designer drugs seem to be more active in serotonergic transmission and
less in dopaminergic and adrenergic. In all cases neither one nor the other are
totally selective32.
In the neurons containing monoamines, the formed neurotransmitter, for example
serotonin, is stored in vesicles situated in the proximity of the synapse. When an
excitatory impulse arrives the contents of these vesicles are released into the
synapse and in that fashion the neurotransmitter can bind to the postsynaptic
receptors to instigate a stimulus. Similarly the neurotransmitter can bind to
presynaptic receptors (in the same neuron that released them and that is
responsible for regulating the quantity of neurotransmitter they should release).
The action of these monoamines ends with the recuperation of the majority of
them by means of a transport protein responsible for collecting them at the
synaptic cleft and introducing them back into the cytoplasm (uptake). Serotonin
transporters (SERT) act at serotonergic neurons, dopamine transporters (DAT) at
dopaminergic neurons and norepinephrine transporters (NET) act at adrenergic
neurons. From the cytoplasm monoamines are introduced into storage vesicles
by means of another vesicular transport system (VMAT-2). Amphetamine
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analogues have the capacity to reverse the flow of the VMAT-2 system, in a way
that empties the contents of the vesicles to the cytoplasm and releases them
from there to the synapse. In this way they produce a release of monoamines.
Just as it seems that these types of substances can enter into the neuron by
means of the aforementioned membrane transporters, they also interfere in the
process of uptake and because of this act as inhibitors of the same transport
system. While MDMA and its derivatives bind principally to SERT rather than
DAT (affinity constants of 0.35 uM and 1.14 uM respectively), other
amphetamines have a higher affinity for the DAT transporters than the SERT
(affinity constants for amphetamine are 0.13 uM and 4.51 uM respectively).
However, taking this selectivity into account, the quantity of dopamine liberated
by MDMA is more than that of serotonin because dopaminergic neurons are
more plentiful than serotonergic ones in most areas of the brain32.
Moreover, MDMA inhibits the enzyme tryptophan hydroxylase which is the
limiting step in the synthesis of serotonin33. In this way, MDMA provokes an
important release of serotonin, impedes its uptake and rapidly produces an
exhaustion of the reserve serotonin vesicles combined with a decrease in its
synthesis. The result is an initial increase in serotonin followed by a decrease
some 2-4 h later, which persists more than 24 h. Additionally, MDMA has a
certain activity as a monoamine oxidase A (MAO-A) inhibitor34. MDMA and its
derivatives are also agonists of a2-adrenergic receptors, MI muscarinic receptors
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Figure 1.3. Pathways of 3,4-methylenedioxymethamphetamine (MDMA) metabolism in
humans. The parent compound is N-demethylated to form 3,4-methylenedioxyamphetamine
(MDA) and O-demethylenated to form 3,4-dihydroxymethamphetamine (HHMA). HHMA is
further O-methylated to 4-hydroxy-3-methoxymethamphetamine (HMMA). Abbreviations:
CYP = isozyme of cytochrome P450; COMT = catechol-O-methyl transferase; HMA = 3-




1.3.2. MDMA metabolism and pharmacokinetics
1.3.2.1. In vitro metabolism
The main pathways of MDMA metabolism are shown in Figure 1.3. MDMA is N-
demethylated to form 3,4-methylenedioxyamphetamine (MDA) and O-
demethylenated to form 3,4-dihydroxymethamphetamine (HHMA) by isozymes of
cytochrome P450. HHMA is highly unstable and conjugates with sulphate and
glucuronic acid. HHMA can also be oxidised rapidly to its corresponding quinone
and form adducts with glutathione and other thiol-containing compounds35.
HHMA is further O-methylated to form 4-hydroxy-3-methoxymethamphetamine
(HMMA) by catechol O-methyltransferase (COMT). MDMA metabolism has been
studied in rat, rabbit and human liver microsomes, in cytochrome P450
expression systems and recombinant enzymes36"39. MDMA is predominantly N-
demethylated to MDA in rat liver microsome preparations with cytochrome P450's
of the CYP2D and CYP1A families involved in this step. In the rabbit, the main
metabolic route is O-demethylenation to HHMA. In human systems the main
cytochrome P450's identified in MDMA metabolism were CYP2D6, CYP1A2,
CYP3A4 and CYP2B6, with MDMA being both N-demethylated and O-
demethylenated. The O-demethylenation step is predominant and presents
biphasic kinetics with the high affinity component controlled by CYP2D6 and a
low affinity component controlled by CYP1A2 with contributions by CYP3A4 and
CYP2B6. Human microsomal maximal velocities for N-demethylation are far
lower than for O-demethylenation and are characterised by monophasic kinetics.
The most important isozyme for this reaction appears to be CYP2B6. Although
MDMA displays the highest affinity for CYP2D6, CYP1A2 seems to have the
highest rate of O-demethylenation. Studies have also investigated MDMA's
inhibition of its own metabolism. The inhibitory complex of CYP2D6 and MDMA
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1.3.2.2. In vivo metabolism and pharmacokinetics: animals
Although there are many studies reporting MDMA and metabolite concentrations
in animals there are fewer presenting pharmacokinetic values due to the difficulty
in serial plasma sample collection. Many differences in metabolism have been
found between species, strain, gender and administration route. Some of the
published pharmacokinetic parameters for MDMA are summarised in table 1.3.1.
In the rat, MDMA is predominantly N-demethylated to MDA, although most of the
metabolites have been identified in urine41. In the Sprague-Dawley rat, following a
10 mg/kg i.V. dose of MDMA hydrochloride, the elimination half-life of MDMA is
1.7 h with a volume of distribution of approximately 7 L/kg. Plasmatic
concentrations of MDA are approximately 20% of MDMA in the rat with 9% dose
excreted in urine. Enantioselective metabolism has also been observed,
favouring the clearance of (S)-MDMA over (f?)-MDMA42. In the rhesus monkey,
following a 1.5 mg/kg i.v. dose of MDMA the Cmax reaches 9000 jig/L at
approximately 1.5 h, the elimination half-life is 1.6 h and a volume of distribution
of 1.74 L/kg. MDMA is predominantly O-demethylenated in monkeys and non-
linear pharmacokinetics has been observed in squirrel monkeys43. Although no
pharmacokinetic data exist for mice the main metabolic route is that of N-
demethylation to MDA. Concentrations of MDMA and MDA are similar to that of
the rat, although the ratio of MDMA to MDA is slightly lower in the mouse44.
1.3.2.3. In vivo metabolism and pharmacokinetics: humans
In humans, MDMA disposition has an important first pass hepatic metabolic
component45. MDMA is predominantly O-demethylenated in humans with about
5% of the oral dose being N-demethylated. The majority of published
pharmacokinetic parameters for MDMA are summarised in table 1.3.2. Some of
the data were obtained from non-controlled or single-case studies. When
interpreting analytic results in correlation with these data, broad individual
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variations must be considered due to variations in metabolic or excretion rates or
due to drug or food interactions. Indeed, although all data come from oral
administrations, differences between whether MDMA was administered in
capsule, tablet or solution will affect the absorption rate of the drug. In summary,
following a 100 mg dose of MDMA hydrochloride in a soft gelatine capsule tmax
was observed at 2 h with maximum concentrations of 200 \ig/L. Mean elimination
half-life is approximately 8 h. Plasma concentrations of HHMA and HMMA are
similar to the parent drug with a Cmax of approximately 180 ng/L and 160 ng/L and
tmax of 1 h and 2 h, respectively46. Following a 100 mg dose peak concentration of
MDA is approximately 13 ¡ug/L and is reached at 5-7 h following administration.
MDMA possesses non-linear kinetics above a certain administered dose.
Concerning this hypothesis, the pharmacokinetic results of a trial where single
increasing doses of MDMA were administered pointed out a disproportionate
increase in the pharmacokinetic parameters (area under the concentration curve
and Cmax) in relation to the dose interval (50-100-125-150 mg)
47. The
pharmacokinetics of MDMA is enantioselective with (S)-MDMA being eliminated
faster than (R)-MDMA48.
1.3.2.4. CYP2D6 and MDMA pharmacokinetics
Cytochrome P450 isoform 2D6 is a heme containing protein of 497 amino acids
in length. It accounts for only a small percentage of hepatic P450's (-10%) but is
responsible for the metabolism of approximately 20-30% of marketed
Pharmaceuticals, including tamoxifen, antidepressants such as imipramine,
nortriptyline, maprotiline and the antianginal agent perhexiline49'50. In the human,
CYP2D6 is postulated to be responsible for 30% of the O-demethylenation of
MDMA to HHMA3. As has previously been mentioned, MDMA presents non-linear
pharmacokinetics in humans, i.e. the plasma concentrations of the MDMA are not
proportional to the administered dose and it tends to accumulate at high doses.
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This is due to the inhibition of its own metabolism. This inhibition has been
observed in vivo where MDMA was administered in two consecutive doses
administered 24 h apart3.
Interindividual differences in CYP2D6 activity were first discovered in the late
1970's and then subsequently proven to be genetic in nature. The clinical
aspects of the CYP2D6 polymorphism were further studied in investigations into
the adverse effects of debrisoquine and sparteine respectively51'52. The complete
characterisation of alíeles CYP2D6*3 and CYP2D6*4 was published in 199153.
Since then, over 70 different alíeles of CYP2D6 have been described. The variant
CYP2D6 alíeles can be classified into categories, which cause abolished,
decreased, normal, increased or qualitatively altered catalytic activity. Among the
most important variants are CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*10,
CYP2D6*17 and CYP2D6*41 and gene duplications. The frequency of CYP2D6
alíeles also varies ethnically. All variant alíeles are presented at the home page of
the human CYP alíele nomenclature committee
(http://www.imm.ki.se/cypalleles/cvp2d6.htm)54. Phenotypically, individuals can
be divided into four categories: poor metabolisers (PM), intermediate
metabolisers (IM), extensive metabolisers (EM) and ultrarapid metabolisers (UM)
according to increasing CYP2D6 activity.
Preliminary data have shown that MDMA pharmacology differs according to
CYP2D6 genotype4. Studies in vitro have shown MDMA intrinsic clearance differs
according to CYP2D6 genotype, with CYP2D6*17 differing in substrate specificity




1.3.2.5. Individual differences in activity of other enzymes involved in
MDMA metabolism
In vitro data show that, MDMA is also O-demethylenated by CYP1A2, CYP3A4
and CYP2B6. CYP1A2 is involved in the metabolic activation of several
carcinogens and its activity differs drastically between individuals due to gender,
ageing, race, genetic polymorphisms and exposure to ¡nducers. CYP1A2 can be
induced by smoking, dietary factors, several drugs and exposure to industrial
chemicals56. CYP3A4 is the most abundant P450 isozyme found in the liver. It is
responsible for the metabolism of benzodiazepines, endogenous steroids and
HIV antiretrovirals among others. Indeed, the involvement in the metabolism of
the latter group of substrates provides the only published observation of a
harmful drug interaction with MDMA57 on account of it being inhibited by the
antiretroviral, ritonavir. Other CYP3A4 inhibitors include grapefruit juice. CYP3A4
is also inducible. CYP2B6's concentration in human liver is very low as compared
to CYP1A2 and CYP3A4 and is mainly responsible for MDMA N-demethylation, a
minor step in MDMA metabolism. Therefore little contribution is expected to
MDMA metabolic disposition. What proportion CYP1A2 and CYP3A4 contribute
to MDMA metabolism in humans has not been investigated.
Catechol-O-methyltransferase (COMT), which is involved in phase II MDMA
metabolism, also displays polymorphic activity. A change at codon 158 in the
COMT gene encodes for a low activity enzyme. This polymorphism exhibits
autosomal inheritance in the population, with approximately 25% of individuals
possessing the low activity haplotype in the Caucasian population. Another 25%
possess the COMT ultrarapid haplotype. COMT inactivates HHMA giving rise to
HMMA and so any differences in its activity may result in interindividual
differences in the effects of this reactive catechol.
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1.3.3. Controlled clinical trials with MDMA
1.3.3.1. Administration of MDMA at single doses
The first published controlled clinical trial using MDMA was by Grob et al.,58. In
this trial MDMA was administered orally in doses of 0.25, 0.5, 0.75 and 1 mg/kg
of body weight to healthy volunteers. The effects of MDMA were evaluated
through physiological parameters (heart rate (HR), blood pressure (BP), body
temperature (T) and neuroendocrines (PRL and ACTH)). The results showed a
rise in HR, BP, PRL and ACTH following the administration of MDMA.
In 1998 a clinical trial was published in which a dose of 1.7 mg/kg of MDMA was
administered orally, with a dose interval of 90-150 mg59. Physiological and
subjective variables were studied. With respect to the physiological variables, the
administration of MDMA produced an increase in systolic blood pressure of
between 10 and 30 mmHg and an increase in diastolic blood pressure of
between 5 and 10 mmHg. Body temperature increased somewhat although
showed no evidence of significant change in respect to the placebo. In a number
of the positive subjective effects a sensation of well being, an improvement in
humour and an increase in emotional sensitivity were noticeable. Amongst the
acute adverse effects were a slight anxiety, episodes of unawareness and
depersonalisation, a moderate alteration in thought processing, alterations in
spatial and temporal perception, although true hallucinations were not observed.
After the first 24 hours of the clinical trial, the noticeable psychological effects
were insomnia, weariness and a slight difficulty in concentration.
In 1999 and 2000, results from the first clinical trial performed in Spain with
MDMA were published60'61. The clinical trial was conducted following a double
blind, crossover, placebo-controlled design. Amphetamine sulphate
(Centramina®) was also used as a positive control. The treatment was
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administered randomly according to a 4 x 4 balanced Latin square system. The
volunteers participated in four sessions (one for each condition of treatment) and
the blank period between sessions was at least one week. The treatments
received were two doses of MDMA (75 and 125 mg), one of amphetamine
sulphate (40 mg) and placebo. These doses were selected following the results
obtained from a pilot study in which MDMA was administered at doses of 50, 100
and 150 mg, amphetamine sulphate at doses of 20, 30, 35 and 40 mg and
placebo. The variables studied consisted of physiological parameters,
psychomotor output tests, questionnaires on subjective effects, neuroendocrine
parameters and analysis of plasma and urine of psychoactive drugs.
For the physiological variables results showed an important increase in blood
pressure and heart rate, as much for MDMA as with the administration of
amphetamine sulphate. With regards to blood pressure, amphetamine sulphate
produced some results comparable in magnitude and in temporality to the high
doses of MDMA (maximum effect at 1.5 h post administration). The heart rate
also showed an important increase during the three active conditions compared
to the placebo. Once again the maximum increase was similar in magnitude for
the high dose of MDMA and amphetamine sulphate, although the temporal
course showed differences between the two substances. Thus, while for MDMA
the maximum effect was produced around the first two hours, in the case of
amphetamine sulphate it was produced from 8 hours post-administration. The
temperature did not show distinct changes in respect to the placebo for any of the
conditions of treatment, even if graphically a slight increase is observed, more
evident with amphetamine sulphate. Evidence of a distinct increase in pupil
diameter was observed in the doses of MDMA in respect to the placebo and
amphetamine sulphate, reaching its maximum between 1 and 2 h post-
administration. Amphetamine sulphate induced a significant increase, although
being less than that observed for MDMA, in the eight hours post-administration.
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The psychomotor tests showed a slight improvement in the output with
amphetamine sulphate and a slight deterioration with the higher dose of MDMA.
However, the results of the statistical analysis only reflected differences in
comparison to the high dose of MDMA in respect to placebo for the Substitution
of Digits for Symbols Test (DSST). The maximum effects were reached, for all
the tests, between 1 and 2 h post-administration. A level of esophoria for the
higher dose of MDMA was observed during the Maddox Wing test, its maximum
effect being produced between 1 and 2 h post ingestion.
With respect to the subjective effects, MDMA induced a dose dependent increase
in the representative scores for the variables of euphoria (Visual Analogue
Scale): VAS "high", VAS "liking", subscale MBG (euphoria) of the Addiction
Research Centre Inventory (ARCI). In VAS "stimulated", an increase was seen in
the score for this scale in respect to the placebo as much for MDMA as for
amphetamine sulphate. As regards the variable that expressed intellectual
efficiency (ARCI-BG), amphetamine sulphate showed an increase compared with
placebo and the higher dose of MDMA produced a decrease in score for this
subscale. The variables that expressed sedation (VAS "drowsiness", ARCI-
PCAG) did not show any statistically significant result in respect to placebo,
although a slight increase (above all in the PCAG) is observed in the scores for
the highest dose of MDMA and a slight decrease in sedation for amphetamine
sulphate. In the variables representing dysphoria (ARCI-LSD), MDMA produced
an increase in score in this subscale in comparison to placebo. Finally, with
respect to the alterations in sensory perception, only the highest dose of MDMA
induced noticeable increases in some of the corresponding scales (VAS
"sensation of altered body state, different or unreal", VAS "changes in shapes",
VAS "changes in light perception", and VAS "changes in audition"). For all of the
variables of subjective effects, the maximum effect was situated between the first
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and second hour post-administration. Hallucinations were not observed for any of
the treatments administered.
With respect to the hormones studied, only MDMA produced noticeable
increases compared to placebo in the plasma concentrations of cortisol and
prolactin. As for the conclusions of the study, it can be affirmed that MDMA is a
substance that presents a high potential for abuse. With respect to the subjective
and psychomotor output effects, MDMA does not correspond to the profile of a
typical stimulant or to one of a hallucinogen, although it possesses more
characteristics of the former group than that of the latter. Finally, the alterations
observed in the physiological parameters confer it with an elevated cardio toxic
potential, without evidence of being a hyperthermic or hallucinogenic substance
at recreational doses and in controlled conditions.
Trials conducted with MDMA have also been published in the USA. RT. Jones'
group administered doses of 0.5 and 1.5 mg/kg body weight to male and female
subjects62-63. C.R. Schuster's group administered 75, 110 and 145 mg per 70 kg
body weight (1.1-2.1 mg/kg) to both male and females64 showing similar
increases physiological and subjective to previous studies, while also reporting
the positive reinforcing effects of the drug at higher doses. In Great Britain, Henry
and Cowan's group administered 40 mg of MDMA to male subjects28 with the
conclusion that even at low doses MDMA induces the release of vasopressin, a
hormone associated with an acute hyponatraemia found in MDMA toxicity
cases65. W.ü. RiedeFs group in Holland have administered single doses of 75 mg
of MDMA to a group of male and female subjects66. Severe or non-expected




1.3.3.2. Administration of MDMA at multiple doses
In an attempt to mimic the "binging" practice as reported for humans in a
recreational setting, three distinct clinical trials have been conducted in which two
separate doses of MDMA was administered with an interval of 2 h (50 mg and
100 mg), 4 h (50 mg and 100 mg) and 24 h (100 mg and 100 mg)3'67.
The pharmacodynamic results showed an existence of an elevated tolerance for
the effects of the second dose of MDMA with respect to heart rate. As regards
other cardiovascular and subjective effects, the effects of the second dose are
greater than those of the first, but less than expected taking into account the
plasma concentrations reached. However, in the case of body temperature,
muscular tension (Maddox Wing) and psychomotor output, it seems that the
effects are equal or superior to those expected considering the concentrations of
MDMA in the blood. Serious undesired or unexpected effects were not observed
in any of the participants.
With respect to the pharmacokinetics of MDMA and it metabolites, in all three
studies it was observed that the concentrations of MDMA following the second
dose were between 15% and 30% higher than those expected by
pharmacokinetic superimposition. The concentrations of HMMA (in all three
studies) and those of HHMA (the latter were only available for one of the studies)
were much less than expected, in a way that the formation of these metabolites
seemed to be inhibited. It has been previously mentioned that MDMA acts as an
inhibitor of its own metabolism, by forming a complex with CYP2D6. This
inhibition produced a 50% reduction in the concentrations of HMMA and lasts at
least 24 hours. The result that the concentrations of MDMA only increased 15-
30% while those of HMMA decreased by 50% indicates that CYP2D6 is mainly
responsible for the O-demethylenation of MDMA. This suggests that the
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remaining O-demethylenation of MDMA in humans is, as has been shown in
vitro, carried out by other enzymes, presumably by CYP1A2 and CYP3A4.
1.3.3.3. Drug-Drug interaction studies
Alcohol
A clinical trial was conducted following double blind, double simulation, crossover
design68. It was placebo controlled and randomised according to a balanced 4 x 4
Latin Square design. The volunteers participated in four sessions (one for each
condition of treatment) with the wash-out period being no less than one week
between sessions. The condition of treatment that the participants received were
MDMA placebo + alcohol placebo (placebo condition), 100 mg MDMA + alcohol
placebo (MDMA condition), MDMA placebo + 0.8 mg/kg of body weight alcohol
(alcohol condition) and 100 mg MDMA + 0.8 mg/kg of body weight alcohol
(interaction condition). The doses of alcohol and MDMA were selected from the
results obtained from a pilot trial in which MDMA was administered at doses of 75
mg and 100 mg and alcohol at doses of 0.5 and 0.8 mg/kg of body weight. The
administration schedule was the following: MDMA or placebo was administered
together with 100 ml of mineral water at the basal time (0 h) and at 30 min the
participant began to drink from a graduated glass containing either alcohol or
placebo. The volunteers drank in a continuous rhythm (117 mL every 5 minutes)
ending the ingestion of the drink at 45 min from the basal time. The drink
containing alcohol contained a combination of vodka (Absolut®, Ahus, Sweden,
40% ethyl alcohol), tonic water (Schweppes®, Madrid, Spain) and lemon juice,
adjusted to a fixed volume of 350 mL. The alcohol placebo was prepared in the
same fashion but without the addition of 0.8 mg/kg of alcohol. With the intention
of masking the fact that alcohol was missing 5 mL of the vodka was rubbed to the
edge of the glass using a piece of cotton wool. Finally, to improve the deception
the drinks were served very cold. The variables of the study consisted of
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physiological parameters, psychomotor output tests, and questionnaires on
subjective effects, neuroendocrine parameters and analysis of the substances in
plasma and urine.
In a number of the results from the physiological variables, MDMA increased
blood pressure as much as the combination of MDMA-alcohol, while the
combination produced a greater increase in heart rate than MDMA alone. MDMA
and the combination produced a similar increase in pupil diameter, while none of
the active conditions produced significant changes in body temperature with
respect to the placebo. Alcohol, however, produced a worse DSST result and
induced exophoria. In a number of the results of subjective effects, MDMA
increased the sensation of euphoria as much as the combination of MDMA-
alcohol according to the ARCI-MBG questionnaire and the VAS "liking". In
comparing the two conditions it was observed than the combination provoked
some longer lasting effects than MDMA alone. The alcohol increased the
sensation of drunkenness according to VAS "drunk" and sedation according to
the ARCI-PCAG and VAS "sedation". The administration of the combination
reversed the sedative effects of the alcohol but did no reverse effects of
drunkenness. None of the active conditions produced hallucinogenic effects. As
for conclusions of this study, it can be confirmed that the combination of MDMA
and alcohol induces greater effects concerning heart rate than MDMA alone.
Also, the combination produces a greater euphoric sensation than either one of
the substances when taken separately. Finally, according to the results observed,
the combination of MDMA and alcohol seems to have a greater potential for
abuse than the two substances when taken separately. In a number of the
neuroendocrine variables, the plasma concentrations of cortisol and prolactin
increased following the administration of MDMA in a similar fashion to the
increase observed during the single dose study. In this way, the combination did
not induce changes in comparison to MDMA alone.
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With respect to the pharmacokinetics, the plasma concentrations of alcohol,
following the administration of the combination were less than those reached
following the administration of alcohol alone. On the contrary, the concentrations
of MDMA were greater and those of HMA less following the administration of the
combination.
SSRI's
Vollenweider's group published a clinical trial reporting the interaction of MDMA
and the SSRI citalopram. A dose of 1.5 mg/kg MDMA was administered orally
along with 40 mg i.v. citalopram in a double blind placebo controlled trial in 12
male and 4 female volunteers. Citalopram pre-treatment reduced but did not
completely abolish the cardiovascular and vegetative side-effects produced by
MDMA6970.
Previous results in multiple dose studies encouraged the completion of a study to
evaluate the importance of CYP2D6 in the O-demethylenation of MDMA.
Consequently a clinical trial was designed in which the metabolism of MDMA was
inhibited by means of administrating paroxetine46-71 followed by MDMA
administration. The trial also studied pharmacodynamic parameters with this
metabolic interest in mind. It was suspected that MDMA enters the neuron by
binding to SERT. Hence, previous administration of an inhibitor of this
transporter, for example paroxetine may influence the effects of MDMA.
The results showed that the administration of paroxetine inhibits the metabolism
of MDMA. The plasma concentrations of MDMA increase approximately 15%
while the concentrations of HMMA are reduced by more than 50% and those of
HHMA up to 20%. The results are very similar o those observed in the study
using repetitive doses of MDMA. This reinforces the theory that MDMA inhibits
CYP2D6, and this isozyme is responsible for 30% of the O-demethylenation of
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MDMA. The previous administration of paroxetine produces an important
decrease in the cardiovascular and pleasant subjective effects of MDMA.
Paroxetine reduced the cardiovascular effects produced by MDMA by
approximately 50% and the interaction with paroxetine reduces the increase in
pupil diameter mediated by MDMA by approximately 70%. During the paroxetine
condition, the increase in temperature shown during the administration of MDMA
alone decreased by approximately 50%. Furthermore, the concomitant
administration of paroxetine produced a marked and significant reduction in the
euphoric and pleasurable effects of MDMA and some feelings of dysphoria.
Recently a study has been published by Tancer and Johanson72, where a dose of
1.5 mg/kg MDMA was administered orally following 20 mg p.o. fluoxetine in a
double blind placebo controlled trial in 8 male volunteers. Fluoxetine treatment
attenuated most of the positive-like subjective effects. In addition, heart rate but
not blood pressure increases were reduced.
Offers
Other controlled clinical trials reporting interactions are those carried by
Vollenweider and Liechti with the dopamine D2 antagonist haloperidol and the 5-
HT2A/c antagonist ketanserin
73'74. In the former, 14 healthy volunteers were pre-
treated with a 1.4 mg i.v. dose of haloperidol before a dose of 1.5 mg/kg p.o.
dose of MDMA. Haloperidol attenuated MDMA-induced positive and mania-like
mood changes but had no reducing effect on other subjective and cardiovascular
effects. In the latter, 50 mg p.o. ketanserin was administered previously to a dose
of 1.5 mg/kg p.o. dose of MDMA in 14 healthy volunteers. The serotonin receptor
antagonist attenuated the perceptual changes, emotional excitation and some
acute adverse responses caused by MDMA but had little effect on positive mood,
well being and extroverted behavioural changes induced by MDMA.
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1.3.4. MDMA acute toxicity
Perhaps the most predominant severe acute adverse effect following ingestion of
MDMA by recreational users is hyperthermia, which can lead to such problems
as rhabdomyolysis, myoglobinuria and renal failure, liver damage and
disseminated ¡ntravascular coagulopathy75. These problems are a feature of
heatstroke and have been observed for other amphetamines and can lead to
death in some cases. Although it is one of the major symptoms of MDMA acute
toxicity with body temperatures of up to 43°C being reported, such changes
generally only occur at higher doses. Mas et al.60 did not observe changes in
body temperature at a dose of 125 mg, while Vollenweider et al.,59, giving a dose
of 1.5 mg/kg, did. However, MDMA is usually consumed in dance clubs or
"raves", where the hot and crowded conditions where people engage in very
active dancing may alter this value.
Many studies in animals report an acute dose-dependent hyperthermic
response76. Some investigators have reported a hypothermie response although
this difference may be due to the temperature at which the animals were housed
at. Higher room temperatures result in rats having a hyperthermic response
whereas lower temperatures result in a hypothermie response. Both responses
have also been observed in mice but the result tends to be strain and dose
specific. These observations lead to the conclusion that MDMA does not cause
hyperthermia per se but in a more general fashion interferes with
thermorégulation.
The hyperthermic response has also been studied following what can be defined
as a repeated binge dosing regimen. The data obtained however have been
somewhat contradictory. Dafters77 gave daily doses of 7.5 mg/kg during 13
consecutive days and reported an increase in peak temperature over time. In
contrast, a more intense dose regimen of 10 mg/kg every 2 h for a total of four
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injections caused an inhibition of the hyperthermic response to a subsequent
MDMA challenge. A prior single dose of 12.5 mg/kg MDMA resulted in a
challenge of 5 mg/kg MDMA producing a greater hyperthermic response in rats
housed at 30°C than in non-pre-treated animals. Repeated MDMA administration
(2, 4 or 6 mg/kg x 3) produced dose-dependent hyperthermia in rats housed at
19°C, with MDMA (2 mg/kg x 3) having little effect. However, this dose produced
significant hyperthermia in rats housed at 30°C following the third dose. A prior
single dose of MDMA (12.5 mg/kg) resulted in MDMA (2 mg/kg x 3) producing
marked hyperthermia after the first dose and severe hyperthermia after the third
dose78.
It is generally assumed that hyperthermia is associated with increased 5-HT
release, although recent evidence suggests dopamine release is the principal
mechanism. Indeed, administration of 5-HT uptake inhibitor fluoxetine produces a
major inhibition of MDMA induced 5-HT release but does not affect the
hyperthermic response79. Furthermore, most 5-HT receptor antagonists fail to
antagonise MDMA-induced hyperthermia. These preclinical data are generally
consistent with the findings in humans74. However, the dopamine D1 receptor
antagonist SCH23390 is an effective antagonist of the hyperthermia in rats79. The
hyperthermic response also differs in animals which are housed separately or
together80, evidence which has consequences for the way in which MDMA is
taken by humans. Conversely, the heightened locomotor response caused in
animals administered with MDMA does not seem to be linked with hyperthermia.
At a cardiovascular level, MDMA can cause in humans arterial hypertension,
tachycardia, arrhythmia, myocardial ischemia (angina) and acute myocardial
infarction. Cephalea, trembling, muscular tension and chewing, vertigo, ataxia
and dystonia can also be observed. Moreover, MDMA has been attributed to
aplastic anaemia, retention of urine, mandibulary joint injury, dental erosion and
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facial muscle pain. At the gastrointestinal level nausea and vomiting may be
caused.
At the psychological level dysphoria, insomnia, irritability, agitation, hostility and
confusion may be caused. Psychiatric trauma includes anxiety, distress and
delirium. References to certain types of paranoia and hallucinations have been
made. At the disappearance of the euphoric effects or at the end of use, the
typical residual effects that appear are; fatigue, difficulty in concentrating,
anorexia, apathy, insomnia, loss of memory, unwillingness to work/study,
irritability, depression, muscular pain and a loss of sexual desire81.
Other serious alterations are malignant neuroleptic syndrome and serotonin
syndrome, due to an excess of serotonin in the CNS. It is clinically noticed by the
appearance of at least three of the following symptoms: confusion, fever,
trembling, diaphoresis, ataxia, hyperreflexia, myoclonus and diarrhoea81.
Evidence suggests that MDMA use is one of the primary causes of hepatitis
among young people82. Amongst other potentially fatal effects are
subarachnoideal haemorrhage, intracranial haemorrhage, cerebral infarction and
thrombosis of the cerebral ventricular cavity. Among the implicated mechanisms
are, hypertension, the possible swelling of the cranial blood vessels and or
dehydration.
Dehydration is produced usually due to the high temperatures of the places
where MDMA is habitually consumed and the elevation of body temperature
caused by dancing. In this case, the users drink water to assuage these
unwanted effects. However, cases of cerebral oedema and hyponatraemia have
been described, which are secondary causes of an inadequate secretion of
antidiuretic hormone (vasopressin) induced by MDMA28. This induces thirst and
the consumption of inadequately large quantities of water which leads to
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hyponatraemia. Both MDMA and its metabolites, particularly HMMA are inducers
of vasopressin secretion83.
In humans, MDMA acute toxicity has been associated with elevated plasma
concentrations84. Interindividual differences in metabolism due to differences in
activity caused by the genetic polymorphisms of CYP2D6 could contribute to
differences in the toxicity profile to MDMA between subjects, for example in the
hyponatraemic response or hyperthermia. Indeed, an increased hyperthermic
response is observed in an animal model for CYP2D6 PM85. The duration of
CYP2D6 inhibition by MDMA must also be considered in the context of patterns
of use, i.e. that of "binging". If it lasts more than one week then a subject who
binges or takes MDMA in two subsequent weekends may not present a toxic
response following the first dose but the following week may present such a
response, especially if the hyperthermic results found in animals are to be
believed.
1.3.5. MDMA neurotoxicity
The neurotoxicity associated with MDMA is concerned with long-term reductions
in markers of the serotonergic system activity. These reductions have been
observed in rats and non-human primates, with non-human primates being more
sensitive to the neurotoxic effects. They include the decrease in cerebral 5-HT
and its major metabolite 5-HIAA, decreases in 5-HT uptake transporters (SERT),
decreases in tryptophan hydroxylase activity and loss of serotonergic axons in
the striatum, neocortex and thalamus86. However the failure to demonstrate
gliosis, the classic marker for neurotoxic brain injury, raises doubt on the validity
of this model of brain "damage"87. Although it is difficult to relate the latter findings
to the human there is growing consensus that MDMA is neurotoxic in the human.
Differences have been seen in cerebrospinal fluid 5-HT and metabolite
concentrations of MDMA users compared to that of controls that never used
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MDMA88. Additionally, PET imaging techniques have demonstrated changes in 5-
HT uptake sites in ex-MDMA users compared to controls. These results have
been controversial because of the small sample size, large variation and signal to
noise found in such studies89. Recent studies seem to confirm previous findings,
with two additional aspects to be considered: changes in 5-HT uptake are related
to MDMA intensity of use and that recovery over time is observed in these
alterations90. Even so, studies in humans are littered with methodological
problems such as the confounder of polydrug abuse and the possibility of pre-
existing differences between users and controls.
Neurotoxic effects of amphetamines on monoaminergic systems have been
associated with the formation of reactive oxygen species (ROS)5. The
administration of antioxidants such as ascorbic acid, selenium and vitamin E can
attenuate MDMA-mediated neurotoxicity while the inhibition of Superoxide
dismutase (SOD) may potentiate toxicity91"94. In transgenic mice expressing
human SOD, methamphetamine induced neurotoxicity in the dopaminergic and
serotonergic systems is attenuated when compared to control animals95
suggesting that Superoxide radicals contribute to these adverse effects. However,
there is a debate as to what is the source of these ROS. In recent years, a broad
amount of evidence appears to indicate that reactive oxygen species generation
responsible for 5-HT depletion is dependent upon the prolonged and excessive
release of DA elicited by MDMA8. It is known that DA can enter the 5-HT terminal
by means of the 5-HT transporter96'98 and once inside the 5-HT terminal, be
deaminated by MAO-B resulting in an elevated intracellular level of hydrogen
peroxide that is reduced by iron to produce hydroxyl radicals and a subsequent
terminal degeneration8'96'99. Explaining why MDMA-induced 5-HT depletions also
occur in regions such as the hippocampus or frontal cortex, which are sparsely
innervated by DA, is the main drawback of this hypothesis. This important issue
has been expanded upon recently100. These authors showed that MDMA
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increases the concentrations of tyrosine in the brain to cause a long-term
depletion of 5-HT via the nonenzymatic, tyrosine hydroxylase-independent,
hydroxylation of tyrosine to DOPA and subsequently to DA via amino acid
decarboxylase. However, this latter hypothesis assumes the pre-existence of
hydroxyl free radicals responsible for the oxidation of tyrosine to DOPA.
There is also a close relationship between hyperthermia and neurotoxicity
engendered by MDMA6'7'101. The blockade of MDMA-induced hyperthermia is the
only common link among drugs with disparate mechanisms of action known to
prevent MDMA toxicity33'102"109. Furthermore, small changes in ambient
temperature cause large changes in MDMA-induced 5-HT neurotoxicity and core
body temperature in the rat6'110. Similarly, other non-pharmacological
manipulations that prevent the acute hyperthermic response caused by MDMA
also provide substantial protection against the serotonergic neurotoxic effects of
MDMA111. However, the free radical trapping agent, a-phenyl-A/-tertbutyl nitrone
and the serotonin uptake inhibitor fluoxetine, partially prevent MDMA-induced
serotonergic changes without modifying hyperthermia112'113. Indeed, MDMA
aside, free radical formation in the brain is influenced by body temperature and
lowering the body temperature results in decreased free radical formation114'115.
Taking all this evidence together it appears that hyperthermia has more of a
modulating role in MDMA-induced neurotoxicity. Other hypotheses of MDMA-
induced neurotoxicity have also been proposed, including dysregulation of
energy metabolism9'10 and the induced release of glutamate and nitric oxide86.
Not only does MDMA induce DA secretion but its own metabolism generates a
catechol in the form of HHMA, which can further oxidise to its corresponding
quinone, N-methyl-a-methyldopaquinone, that may participate in MDMA induced
neurotoxicity (Figure 1.4)116. Similarly, the metabolism of MDA gives rise to a-
methyldopaquinone. The quinone products of HHMA and HHA are further
conjugated to glutathione and or cysteine116. The formation of thioethers of these
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quiñones lowers their redox potential and increases their ability to redox cycle
and to generate ROS35. Such electrophilic redox-active quiñones may contribute
to the damage to serotonergic and DA nerve terminals, their transporters and to
the inhibition the tyrosine-hydroxylase. This inhibition may be achieved by
modifying proteins at the post-translational level, by converting them to
quinoproteins117. A neurotoxic metabolite of this kind has been identified in the rat
brain11. Further evidence that the metabolism of MDMA contributes to its
neurotoxicity is evidenced by the fact that the neurodegeneration of the
serotonergic system is only evident when the drug is administered systemically
but not when administered directly to the brain118'119.
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When discussing MDMA-induced neurotoxicity, a variable that must be taken into
account is the prevalence and pattern of use as seen in humans. Data in humans
has shown an association between intensity of use and SERT loss90. Indeed, in
many studies the heavier users are those that differ from controls. Furthermore,
repeated dosing is the preferred procedure in animal studies to induce



















Figure. 1.4 Proposed mechanism for free radical (ROS) formation that leads to neurotoxicity
from the metabolism of MDMA and dopamine. When R = -CH?-CH:,CH-NH-CH t it corresponds




intense MDMA use or binging therefore could result in an almost permanent
inhibition of CYP2D6 in an EM subject, rendering any functional differences due
to genetic polymorphisms redundant. Indeed, interindividual differences in other
enzymes such as CYP1A2 and COMT could play a more important role in
neurobiological changes noted for humans.
1.3.5.1. Problems with relating animal and human data
It has often been asserted in forums of recreational ecstasy users that data on
adverse effects of MDMA obtained in experimental animals are not relevant to
human use, as the doses administered have been much higher than those used
by humans. While it is undoubtedly true that many experimental studies have
used high doses, it now appears that different strains have different
susceptibilities to the drug. Furthermore, recent studies have demonstrated
neurotoxicity in rats following doses that are a fraction of those used in the earlier
studies123. It is always difficult to make direct comparisons between results
obtained in animal and human studies, since small mammals tend to eliminate
drugs at a faster rate than large mammals. However, it has been suggested that
the technique of interspecies scaling124 enables prediction of drug elimination in
different species based upon the underlying anatomical, physiological, and
biochemical similarities among most land mammals. Thus, to achieve a similar
effect to that seen in humans, smaller animals require higher doses of drug,





Where D = dose of drug in milligrams and W = body weight in kilograms.
According to this equation, a single neurotoxic dose of MDMA (5 mg/kg)
administered to a 1 kg monkey can be calculated to equate to a dose in a 70 kg
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human of 98 mg or 1.4 mg/kg125. A dose of MDMA of 10 to 15 mg/kg that
produces substantial damage in the brain of Dark Agouti rats is thus equivalent to
a human dose of 140 to 190 mg in a 70 kg human. However, the validity of
interspecies dose scaling in relation to MDMA has been argued against by other
authors who state that calculations of dose equivalency should be based on the
minimal dose which causes a pharmacological effect. In the case of animal
models, doses as little as 1-2 mg/kg cause distinct behavioural effects in rats126,
yet no long-term serotonergic changes have been observed as these doses.
Furthermore, there are many differences in in administration route,
pharmacodynamic response, metabolism and pharmacokinetics between animal
studies and MDMA user practice. Although ecstasy is taken orally in tablet form,
the majority of animal studies are conducted using other routes of administration
usually intra-peritoneal. It is also interesting to note that according to interspecies
scaling the dose which causes a notable hyperthermic response in animals does
not cause such a drastic response in humans. On a metabolic and
pharmacokinetic level, following administration of MDMA to mice, MDMA is the
main chemical species observed in both plasma and brain. By contrast, although
MDMA is observed in rats and humans following its administration, HHMA and
HMMA, which are produced at different rates in rats and humans, are also
present in high concentrations in plasma. In fact, MDMA metabolism, except in
mice, is qualitatively similar for its major metabolic reactions in most animal
species and humans; nevertheless, there are relevant quantitative differences. In
rats, the N-demethylation of MDMA leading to the formation of MDA is one of the
main metabolic pathways at low doses127, whereas in humans the O-
demethylenation of MDMA to HHMA predominates at any dose tested45. In rats,
the rate of N-demethylation is dose dependent and at doses higher than 10
mg/kg there is saturation of hepatic clearance127. In monkeys given 10 mg/kg of
MDMA twice daily for four consecutive days, MDMA plasma concentrations
increased by 30% and MDA plasma concentrations increased by 200%,
62
Introduction
compared with levels present following the first dose of MDMA; MDA
concentrations were as high as 18% of the concentration of MDMA122. By
contrast, MDA plasma concentrations are usually <5% of the concentration of
MDMA in humans following administration of MDMA45.
In rats, the enzyme involved in O-demethylenation of MDMA is CYP2D1.
Although this enzyme is homologous to human CYP2D6, the enzymes are not
functionally identical128. Interestingly, although there are no major differences
among animal species in the affinity of substrate probes for this enzyme
(CYP2D1/CYP2D6), there is an approximate tenfold difference in its Vmax for
bufuralol 1-hydoxylase activity. The enzyme in humans has lower Vmax for
bufuralol than the enzyme in rats and monkeys. Furthermore, this activity is
inhibited by quinidine in humans but not in mouse or rat129. Although in humans a
single dose of MDMA can fully inhibit CYP2D6, in non-human primates several
doses of MDMA are required for full inhibition of the enzyme122. Rats and to more
of extent, mice, express many CYP2D isozymes whose contribution towards
MDMA metabolism has not been investigated. Thus, differences in both enzyme
kinetics and the inhibition of CYP2D6 by MDMA through the formation of an
enzyme-metabolite complex suggest that different rates of formation of metabolic
neurotoxic species and different susceptibilities to the development of
neurotoxicity exist among species. Indeed, in mice, in which MDMA
predominates in tissues following its administration, MDMA-induced neurotoxicity
is mainly dopaminergic.
1.4. Assessment of the Activities of CYP2D6 and CYP1A2
Previous investigations have shown that: (1) MDMA users are known to take
more than one pill per session. (2) CYP2D6 activity is impaired by MDMA through
MBI and (3) other isozymes of cytochrome P450 with lower affinity for MDMA






Figure 1.5. Mechanistic scheme for mechanism-based inhibition. Rsys = rate of enzyme
synthesis; Kdeg = degradation rate of the enzyme; [S] = substrate concentration; [P] =
metabolite concentration; [E-S] = enzyme substrate complex concentration; [E] = enzyme
concentration; [I] = inhibitor concentration; [E-l] = inactivated enzyme inhibitor complex;
[E-l] = enzyme inhibitor complex; [P|] = inhibitor metabolite.
have implications for both acute and long-term toxicity of MDMA. Although in vitro
and animal studies give much information about the metabolism of MDMA, for a
full understanding of the system of CYPs involved, human studies are required.
1.4.1. Mechanism-based inhibition
As previously mentioned CYP2D6 is inhibited by MDMA in a quasi-irreversible
fashion in a phenomenon otherwise referred to as mechanism-based inhibition
64
Introduction
(MBI). MBI is also known as suicidal inhibition, irreversible inhibition or time-
dependent inhibition and although it is an unusual occurrence in most enzymes it
is more frequently observed in cytochrome P450 catalysed reactions. A substrate
undergoes a catalytic transformation by the enzyme to a species that, prior to
release from the active site, inactivates the enzyme130. There are three kinds of
MBI: covalent binding to the apoprotein, covalent binding and destruction of the
prosthetic heme group and chelation by alkylation or arylation of the prosthetic
heme group or binding (non-covalently) to the apoprotein (quasi-irreversible). MBI
is generally of greater concern than reversible/competitive inhibition as it can
result in a more profound and prolonged effect than the dose or exposure might
suggest. This is illustrated by a measurable change (1.21-fold) in midazolam
AUC following administration of a low dose oral contraceptive preparation
containing 30 mg/day ethinylestradiol and 75 mg/day gestodene131, both
compounds being mechanism-based inhibitors of CYP3A4. An example of
greater clinical significance relates to mibefradil, a potent mechanism-based
inhibitor of CYP3A4, which was withdrawn from use because of unmanageable
drug interactions. For example, at a relatively low dose of 50 mg/day, mibefradil
increased the plasma AUC of triazolam by 9-fold132. The extent of these
interactions can not be anticipated based on the competitive inhibitory potencies
of the compounds involved. Mechanism-based inhibitors that bind covalently to
CYPs and potentially other proteins via formation of reactive metabolites are of
additional concern due to the risk of idiosyncratic toxicity. For example, tienilic
acid, which is metabolised to an electrophile that binds covalently to CYP2C9,
was withdrawn from use due to hepatotoxicity mediated by an auto-immune
response133. However, MBI is not always associated with the formation of
covalently bound species and the binding may be specific to a GYP. For
example, macrolide antibiotics such as erythromycin are metabolised by CYP3A4
to reactive nitrosoalkanes, which form metabolite intermediate complexes
through co-ordination to the heme of the enzyme134.
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The formation of P450 metabolite complexes upon oxidation of drugs containing
tertiary amine or methylenedioxy functions involves oxidation leading to inhibition
of P450 catalytic activities. Evidence for complex formation by methylenedioxy
compounds was explained by findings from in vitro studies that showed a
decrease in CYP content when microsomal fractions were incubated with
piperonyl butoxide and NADPH. Unusual absorbances near 427 and 455 nm
were detected in microsomal difference spectra during such incubations. Thus, it
was suggested that methylenedioxy compounds undergo CYP-dependent
oxidation and generate complexes with CYP that contribute to the observed
decline in drug and xenobiotic oxidation135. MDMA has the particularity of having
on the same molecule both the tertiary amine and the methylenedioxy functions.
In the case of MDMA the amine moiety may oxidise to a nitroso metabolite which
readily reacts with the Fe (II) of the heme, conversely the methylenedioxy group
can be metabolised to a carbene, forming stable Fe (II) and Fe(lll) complexes40.
However, the nature of the metabolite that is involved in the complexation of
CYPs remains unclear and other possible intermediates have been suggested,
including benzodioxolium ions, homolytic radicals, and carbanions, formed by
oxidation at the methylenic carbon135. Recovery of activity of the enzyme in vivo
depends on de novo synthesis of protein.
1.4.1.1. In vitro assessment of MBI and enzyme activity recovery
Many in vitro studies exist which try to predict the in vivo outcome of MBI134.
Figure 1.5 presents a mechanistic scheme for MBI showing the kinetic
parameters of CYP inactivation, namely the maximum inactivation rate constant
(kinact) and the inhibitor concentration that produces half-maximal rate of
inactivation (K|). Two alternative experimental procedures for investigating the




1. Preincubation of the enzyme and co-factors with different inhibitor
concentrations for varying times, followed by further incubation of a dilution (at
least 1:50) of the reaction mixture with a probe substrate to assess the degree
of enzyme inactivation.
2. As in (1) but with further incubation after direct addition of the probe substrate
to the preincubation mixture, without a dilution step.
An apparent rate of inactivation (kobs) is estimated graphically from the initial
slope of a plot of the natural log of enzyme activity remaining after pre-incubation
against pre-incubation time, corrected for any loss of activity in the absence of





Values of kinact and K, are then obtained from a double reciprocal plot of kobs
against inhibitor concentration. In the case of MDMA a K, of 0.01 h~1and kinact of
0.29 min"1 have been calculated2. A physiologically-based pharmacokinetic model
has been used to calculate a value of 260 h for 90% recovery of CYP2D6 activity
following recreational doses of MDMA136. However, this is based on a number of
assumptions and since the degradation rate constant (Kdeg) or turnover half-life of
a particular CYP in the liver is expression dependent its calculation must be
conducted in vivo.
1.4.1.2. In vivo assessment of MBI and enzyme activity recovery
To monitor the activity of any CYP, the typical experimental approach in vivo is to
use a probe drug, as in vitro. Probe drugs have been used for many years to
distinguish phenotypes of various CYPs. A subject is administered a substrate
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which is specific to a certain CYP and concentrations of the substrate and its
metabolites are measured in plasma and/or urine over a period of time. The
individual is then assigned a phenotype based on the amount of substrate
metabolised. This is usually expressed in a molar metabolic ratio (MR) of
substrate versus metabolite(s) and then compared to a previous decided cut-off
value, or antimode, to assign the phenotype. The change in enzyme activity over
time can be monitored by administering repeated doses of the probe drug and
calculating the MR at each time interval. These values can then be compared to
a basal or control condition, where the individual has not been administered
anything that may alter the activity of a CYP.
As when kinact and KI are calculated in vitro an apparent rate of recovery (Kcyp) is
estimated graphically from the initial slope of a plot of the log of enzyme activity
remaining after administration over time. The following equation defines the rate





Where Kdeg is the degradation rate constant of the enzyme, fu is the fraction
unbound in blood plasma and [I] is the inhibitor concentration. As seen in the
above equation the elimination rate constant of the inhibitor is a function of kinact,
KI and unbound plasma inhibitor concentration.
This equation implies that when the unbound plasma concentration of the
inhibitor is much higher than its KI value and its kinact value is much larger than the
degradation rate constant of the enzyme, CYP activity loss would be 100%
irrespective of the kinetic parameter values and is associated with almost
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complete abolition of drug probe clearance. In this case, the relationship in the
above equation becomes linear, whereby Kcyp « Kdeg. Analysis of data on some of
the compounds that cause MBI of CYP3A (Figure. 1.5) indicated that, depending
on inhibitor strength, variability in Kdeg estimates have a large effect on the
predicted net loss of enzyme activity134. Thus, in situations where unbound
plasma concentrations are lower than the k¡nact and KI the apparent rate of
recovery of CYP2D6 activity to baseline must factor in the mean residence time
of the inhibitor in the system and should reflect two processes: the CYP K^g and
inhibitor elimination rate constant (Kg). The CYP degradation rate constant can
thus be determined using a noncompartmental deconvolution (component
analysis) approach, whereby the mean-residence time (1/Ke) is subtracted from




A half-life estimate of 50 h (range 25-80 h) has been reported for human
CYP2E1 by measuring the time course of return of chlorzoxazone 6-
hydroxylation clearance to baseline following administration of the rapidly cleared
CYP2E1 inactivator disulfiram137. A time course study with three SSRI's that
inhibit CYP2D6 has been conducted138. Following SSRI discontinuation,
calculation of a CYP2D6 inhibition half-life (t1/2¡nh) revealed the time course of
fluoxetine inhibition (t!4¡nh = 7.0 +/- 1.5 days) to be significantly longer than either
paroxetine (ty2mh = 2.9 +/-1.9 h) or sertraline (t
1/2inh = 3.0 +/- 3.0 h) (p < 0.01), but
the latter were not significantly different from each other (p > 0.05). Significant
differences from DEX MR at baseline were measured successfully for up to 35
days in this study. Using the former data for paroxetine139 used in vivo-in vitro
extrapolation to estimate a CYP2D6 degradation half-life of 51 h, but this
0.0001 0.001 0.01 0.1 10
Figure 1.5. Illustration of the ¡nsensitwty (erythromyicin; -»-) or sensitivity (clarithromycin; -
a-) of the predicted decrease in enzyme activity to differences in reported values k0bs- The
simulations were carried out under three different assumptions for the K<jeg value of CYP3A,
corresponding to half-lives of 30, 90 and 270 h, respectively. Source: Ghanbari et al., 2006.
70
Introduction
calculation had many assumptions including the assumption that paroxetine
steady-state concentrations are lower than that its Kifor CYP2D6.
1.4.1.3. Probes for assessing CYP2D6 activity in vivo
The three best known CYP2D6 drug probes are dextromethorphan140 (DEX),
debrisoquine51 and sparteine52. Debrisoquine and sparteine have been used to
phenotype CYP2D6 since the late 1970s, but concerns about availability and
safety have limited their use. Debrisoquine may be the preferred probe for
subjects with high levels of CYP2D6 activity because of its lower turnover
compared with DEX. However, debrisoquine can cause hypotension. On the
other hand, sparteine may be preferred in subjects with impaired renal function
because of its lack of glucuronidation and the fact that it is unaffected by changes
in creatinine clearance. On the other hand, DEX is often used because of its wide
safety margin and ready availability. Some pharmacokinetic studies have
demonstrated that the DEX metabolic ratio is closely correlated with the partial
clearance of DEX to dextrorphan141. In other words, DEX metabolism depends on
CYP2D6 activity and not on renal elimination142. However, the use of the DEX
has not been short of its controversy and its robustness due to differences in















Figure 1.6. Pathways of dextromethorphan (DEX) metabolism in the human.
DEX is a synthetic opioid used as an antitussive. It is primarily metabolised by
CYP2D6 forming dextrorphan (DOR, Figure 1.6). It is also metabolised by
CYP3A4 forming 3-methoxymorphinan (MM). DEX is metabolised to a lesser
extent by CYP3A4 producing 3-hydroxymorphinan (HM), which is also the
metabolic product of MM. In vitro studies from Baculovirus expression systems
suggest that the O-demethylation of dextromethorphan is carried out
predominantly by CYP2D6, with minor contributions from CYP2B6, CYP2C9,
CYP2C18, CYP2C19, CYP2C9 and CYP3A4147'150. During its use as a probe
DEX is usually administered at a sub-clinical dose. DEX and its metabolites are
primarily found in human plasma and urine as glucuronide conjugates. Following
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a dose of 30 mg p.o. dextromethorphan hydrobromide to CYP2D6 EM, total
plasma concentrations of DEX reach a maximum of approximately 2.0 (ig/L at 2.4
h, displaying a tVáe of 2.4 h141. DOR is the main metabolite found in plasma
reaching maximum concentrations of approximately 400 ng/L, followed by HM
with a Cmax of 104 ng/L, with MM being barely detectable in CYP2D6 EM
subjects. In CYP2D6 PM subjects, pharmacokinetics of DEX is quite different,
with DEX being the main compound found, reaching a Cmax of 23.0 ¡ig/L, followed
by DOR with a Cmax of 9.1 ng/L, HM with a Cmax of 4.6 (ig/L and MM with a Cmax of
2.5 (ig/L Following the administration of the CYP2D6 inhibitor, quinidine, plasma
concentrations of DEX in EM subjects are comparable to those of PM subjects.
Concentrations of DEX and its metabolites in urine reflect those in plasma with
27% and 16% of the dose recovered as DOR and HM in CYP2D6 EM,
respectively. In PM, 26% of the dose is recovered as DEX141. The urinary MR of
DEX/DOR has been preferred to plasma concentrations when probing for
CYP2D6 activity because it is less invasive. Various time intervals have been
used for urine collection from 0-4 h up to 24 h. The standard urine collection has
been from 0 to 8 h since the test can be completed in one day and the majority of
the dose would be excreted by an EM individual within this interval. The antimode
for PM phenotype assignment following a dose of DEX is 0.3. In a study of 229
individuals of mixed decent in the U.S. population the mean DEX MR ranged
from 0.001 to 5.980. Within the subpopulation of EM the MR differed some 3000
fold, with two individuals classed genotypically as CYP2D6 EM having a value
greater than the antimode151. Although the DEX MR was able to distinguish EM
from PM well, it was not able to distinguish between those individuals with























1.4.2. CYP1A2 activity and methylenedioxy compounds
As mentioned previously, CYP1A2 is involved in the activation of environmental
procarcinogens, such as arylamines, heterocyclic amines, and aflatoxin B1.
CYP1A2 activity may be considerably increased by xenobiotics, including
cigarette smoke56. Accordingly, as the expression levels of the enzyme
increases, so does the metabolism of certain procarcinogens to DNA-reactive
products, leading to a higher risk of cancer development. On the other hand,
inhibition of CYP1A2 by quinolone antibiotics152, serotonin reuptake inhibitors153,
and oral contraceptives154 may produce adverse reactions when these agents are
administered concomitantly. The MBI caused by MDMA is not an exclusive
property of this compound. Indeed, the inhibitory properties methylenedioxy
compounds have been exploited for some years by using them as pesticide
synergists. These compounds are not pesticides in themselves, their purpose
being to block the metabolism of a pesticide and so increase its strength.
Methylenedioxy compounds are also found as aromatic constituents of oils and
spices. As well as inhibiting many cytochrome P450's, methylenedioxy
compounds have also been known to induce their activity, including that of
CYP1A2155. The mechanism of induction is thought to follow a binding of the
compound to the aryl hydrocarbon (Ah) receptor which accumulates in the cell
nucleus as a heterodimeric complex. The nuclear Ah receptor complex then acts
as a ligand-induced transcription factor which binds to genomic dioxin/xenobiotic
responsive elements (DREs/XREs) located in the S'-regulatory region upstream
from the initiation start site and this interaction results in activation of gene
transcription and an increase in protein expression. On the other hand, evidence
suggesting that rat CYP1A1 regulation is modulated by a protein kinase C
suggested that a phosphorylation cascade mechanism that activates the Ah
receptor may be involved135. Indeed, MDMA has been shown to activate protein
kinase C within synaptic terminals156. Hence, there is reason to hypothesise that
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CYP1A2 could be induced by MDMA. This would have consequences for both
MDMA pharmacokinetics and toxicity and that of other CYP1A2 substrates.
1.4.2.1. The measurement of CYP1A2 activity in vivo
Caffeine is well known as a metabolic probe for CYP1A2157 and it has a high
margin of safety. It has been used extensively in the past to investigate gender
and age differences in CYP1A2 activity158'159 and changes in activity due to
medication, smoking and diet56'152'160. Following ingestion caffeine is essentially
completely absorbed from the gastrointestinal tract. Caffeine is efficiently
eliminated, with a mean systemic clearance of approximately 9 L/min and mean
terminal half-life of 4 h in healthy adults161. Hepatic metabolism is the dominant
elimination mechanism, with less than 5% of an ingested dose being eliminated
unchanged in urine. Caffeine biotransformation is complex, and at least 17
urinary metabolites can be detected following its consumption. The principle
metabolic pathways of caffeine are shown in Figure 1.7. Although CYP2E1,
CYP2A6 and CYP3A4 are involved in caffeine metabolism, 90% of its clearance
is thought to be controlled by CYP1A2. Its clearance in plasma is considered the
"gold standard" for the measurement of CYP1A2 activity in humans. At least six
different urinary metabolic ratios for caffeine have been proposed as in vivo
probes for CYP1A2 activity (Table 1.4.1) and of these the ratio
(AAMU+1X+1U)/17U seems to be the most robust seeing as they are the most
sensitive to changes in CYP1A2 activity and not affected as much by other
enzyme activities or urine flow157. The combination of both caffeine and DEX to
evaluate the contribution of several metabolic enzymes to the metabolic
























Table 1.4.1 Urinary metabolic ratios of caffeine and metabolites used to probe CYP1A2






To investigate the role of MDMA metabolism and its consequences for MDMA
acute and long-term toxicity a series of experiments in animals and humans was
carried out. Due to differences in human an animal CYPs the MBI of CYP2D6
and contribution of CYP1A2 was investigated in a controlled clinical setting and
conversely, due to ethical questions arising from physiological and
pharmacological manipulations of MDMA metabolism, the former studies were
carried out in Wistar rats.
Consequently a series of experiments were designed with the following
objectives to test the following hypotheses:
Hypothesis I
MDMA affects the activities of the cytochrome P450 enzymes responsible for its phase I
metabolism and this has consequences for the acute and long-term toxicities of the drug.
1) Evaluation of the duration of CYP2D6 induced inhibition in humans by
MDMA by using the probe drug dextromethorphan (DEX) in humans.
2) Calculation of the in vivo turnover half-life for CYP2D6 in humans.
3) Investigation the role of CYP1A2 in the metabolism of MDMA in humans
by using the probe drug caffeine.
Hypothesis II
Interindividual differences in the activity of catechol-o-methyltransferase (COMT) are
relevant in the development of long-term toxicity of the drug.
4) Inhibition of MDMA phase II metabolism in the rat using the COMT




MDMA systemic metabolism and not MDMA-induced hyperthermia is the limiting step in
the development of long-term neurotoxicity.
5) The administration of single and multiple doses of MDMA at various
temperatures in rats.
6) The study of the effect of direct application of MDMA into the striatum or
entacapone into the hippocampus in combination with a toxic dosage
regimen of MDMA.
Hypothesis IV
MDMA peripheral metabolism and not the formation of free radicals from
tyrosine/dopamine is the limiting step in the development of long-term serotonergic
changes.
7) Administration of a toxic dose of MDMA or a non-toxic dose of MDMA in
rats and measurement of tyrosine in plasma.
8) The effect of direct application of MDMA into the striatum in combination





3.1. Clinical trial design
3.1.1. Recruitment of the subjects
3.1.1.1. Study sample size and selection
Not knowing the exact effects of the interactions between MDMA and DEX, it was
difficult to calculate the sample size of the study, for this reason a pilot study was
planned. Based on the methodology of bioequivalence studies, with a risk of
alpha value 0.05, power of 80%, variability of 30% and a possible increase in the
plasma concentrations of DEX in the presence of MDMA of at least 40%, it
seemed sufficient to include at least 10 subjects in the final study. The possibility
of retirement or withdrawal from the study of approximately 10% was also
considered and for this reason it was proposed to sample between 12 and 16
subjects (2-4 for the pilot study, 10 for the final and 2 for possible retirement or
withdrawal).
The selection of the volunteers was accomplished three weeks before the
beginning of the trial. Volunteers were recruited by word of mouth. The subjects
were informed as to the characteristics of the study, and they were given an
information leaflet. If they decided to participate they signed a consent form. A
medical examination was then arranged for them which included medical history,
a complete physical exam, psychiatric interview structured according to DSM-IV
guidelines (PRISM), a basic analysis (glucose, creatinine, hepatic enzymes and
bilirubin, CPK, LDH, uric acid, urea, cholesterol, triglycérides, total protein and
albumin, potassium and sodium), haemogram (haemoglobin, red blood cells,
leucocytes), coagulation (platelets, PTT and TP), VSG, basic urine analysis
(glucose, protein, red blood cells, leucocytes, ketone bodies), serology (Hepatitis
B and C, HIV), and 12 lead EGG. The same analysis was carried out at the end
of the study. The CYP2D6 phenotype was determination by means of the DEX
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test (administration of 30 mg DEX hydrobromide and urine collection during the
following eight hours). With the intention of confirming the results from the
previous test, blood samples were collected (1 ml_) a posteriori for DMA
extraction and subsequent CYP2D6 genotyping (DrugMEt®, Jurilab Ltd.,
Finland).
The clinical information from the study was then required to fulfil the following
criteria:
3.1.1.2. Criteria of Inclusion
1. Male volunteers between the ages of 18 and 45.
2. A history or results from a physical exam that demonstrated that volunteers
do not present physical or psychiatric problems.
3. The 12 lead ECG, general blood and urine analyses taken before the trial
should be normal. Small variations within the limits of the norm were
admitted, those that the investigators consider to be without clinical
relevance.
4. The weight of the subject will not exceed 15% of the ideal weight which
corresponds to the subject's height and was between 50 and 100 kg.
5. The acceptance of trial procedures and signature of the consent form.
6. A history of recreational use of 3,4-methylenedioxymethylamphetamine,
having taken "pills" of ecstasy at least 10 times throughout their lives and at
least twice in the last year. No presentation of severe adverse effects during
the use of MDMA.
7. Normal criteria in the psychiatric review (structured interview according to the
DSM-IV).
8. Possession of a phenotype of extensive metabolizer for CYP2D6.
3.1.1.3. Criteria of Exclusion
1. Non-compliance with the criteria of inclusion.
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2. History of abuse or dependence on pharmaceutical or other drugs (except
nicotine) or habitual consumption of psychoactive substances (with the
exception of recreational use of MDMA).
3. Having suffered from any major illness or underwent major surgery in the last
three months before the study.
4. History of possession of psychiatric illness or schizophrenia amongst close
family members.
5. Alcohol consumption exceeding 4 units or 40 g per day for male subjects and
2 units or 20 g per day for female subjects.
6. Smokers of more than 20 cigarettes per day.
7. Subjects presenting intolerance or adverse reactions to coffee.
8. Regular ingestion of medication in the month preceding the study. Single
doses of symptomatic medication were accepted up to the week preceding
the trial (it can be expected that the drug would have been completely
eliminated on the day of the trial).
9. Having donated blood or participated in clinical trials with drugs in the 4
weeks leading up to the trial.
10. History of allergic or adverse reactions to medication.
11. History of gastrointestinal, hepatic or renal problems or any other that may
suspect alterations in the processes of absorption, distribution, metabolism,
or excretion of a drug.
12. Subjects that or not capable of understanding the nature and consequences
of the trial and the procedures that they being asked to follow.
13. Subjects who are serological positive for Hepatitis B and/or C and/or HIV.
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3.1.2. Development of the study
3.1.2.1. Study Preliminaries
Medication
DEX (Romilar®, Roche Farma, SA, 15 mg tablets) was supplied by the pharmacy
of the Hospital del Mar, Barcelona, Spain. Caffeine anhydride was prepared by
the pharmacy of Hospital del Mar, Barcelona, Spain as identically appearing
opaque white, soft, gelatine capsules. (R,S)-MDMA was supplied by the Spanish
Ministry of Health and prepared by the pharmacy of the Hospital del Mar,
Barcelona, Spain as identically appearing opaque, white, soft gelatine capsules.
Capsules also contained lactose. As an internal validation the contents of the
MDMA capsules prepared by the pharmacy of the Hospital del Mar were checked
for concentration and purity. Capsules were analysed according to a modified
method following two previously published protocols (Military standard 105D,
UNE 66020; Recommended methods for testing Illicit Ring-Substituted
amphetamine derivatives, UN, 1987). Briefly, the contents of a capsule of MDMA
were weighed and samples of approximately 10 mg were dissolved in 10 mL ultra
pure H2O (MilliQ). The solution was the agitated and sonicated until full
dissolution. An aliquot of 1 mL was taken and 100 ^L 2M NaOH was added
followed by 10 mL dichloromethane. Samples were agitated for 30 min and
centrifuged at 3500 rpm for 5 min. The aqueous phase was then removed and 50
fil of methanol:HCI (9:1, v/v) was added. Samples were evaporated at 30°C
under a nitrogen stream and reconstituted in 10 mL methanol (solution A). An
aliquot of 1 mL solution A was evaporated at 30°C under a nitrogen stream and
reconstituted in 1 mL 0.1 M H2SO4. Concentrations of MDMA were calculated by
UV spectroscopy using an extinction coefficient of 189.7 with maximum
absorbance of 284 nm, comparing against a standard solution of MDMA treated
with the same procedure. The purity of the sample was checked by an aliquoting
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1 mL solution A into a glass vial and adding 50 jul methylephedrine as internal
standard. 3 ^l were then injected into a GC-NPD system and compared against a
standard solution 10 ng/ml_ MDMA. No other amphetamines or impurities were
found in the capsules apart from lactose. Results of the quantification analysis
are shown in table 3.1.1.
Design
The clinical trial conformed to the declaration of Helsinki (2000), the
recommendations of the OMS, the deontological code and the dérivâtes of
Spanish laws concerning clinical trials (Ley de Medicamiento 25/1990, Real
Decreto 561/1993). The protocol of the clinical trial (IMIMFTCL/MDMA/6) was
submitted and approved by the institutional review board of the IMAS group
(CEIC-IMAS) and authorized by the Dirección General de Farmacia y Productos
Sanitarios (98/112) of the Spanish Ministry of Health (No. aut. AEMPS 04-0013).
Furthermore, as part of a project studying the role of metabolism in the toxicity of
MDMA, the protocol was submitted to the National Institute of Health in the
United States for funding. The project was approved and funding was granted
("Drug metabolism and pharmacogenetics as contributing factors to MDMA-






























Table 3.1.1 Analysis of MDMA capsule content
The design of the study was open since the principal variable is objective
(concentrations of drugs and their respective metabolites). The order of the
sessions was not randomised since it was assumed that the quantity of both
enzymes does not vary in the same subject with time and for this reason was not
necessary.
Subjects were requested to refrain from consuming any drug two weeks before
and throughout the duration of the study and asked to follow a xanthine free diet
48 h before the beginning of each session. At each session and before drug
administration, urine samples were collected to check for the use of drugs of
abuse (opiates, cocaine metabolite, amphetamines, and cannabinoids) by
¡mmunological methods (FPIA, Abbott Laboratories, Chicago, IL, USA). Before
beginning the study sessions, the subjects were familiarised with the subjective
evaluation tests and the questionnaires concerning subjective effects.
Any subjects who presented adverse reactions to the treatment that represented
a danger to their health, in the judgement of the investigator; was retired from the
study. Those who demonstrated a lack of cooperation or who transgress from the
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norms of the study were also retired. The participants could retire from the study
at any moment they wished; in this case it was planned that new subjects could
substitute those abandoned or retired so that the preferred number of inclusions
was obtained for each group treated. Only the results of the volunteers who
concluded the study were considered.
If any subject was taking any other regular medication then a minimum of 30
days was allowed to elapse following the termination of the medication before the
subject could enter the trial. Single doses of symptomatic medication were
accepted up to one week before the trial (it was expected that the ingested drug
was eliminated by day 1 of the trial).
During the trial additional medication was not permitted. It could only be taken
following the prescription of the principal medical investigator or his/her
collaborators (dose, time and cause were noted in a corresponding individual
questionnaire).
3.1.2.2. Pilot phase of study
A pilot study was conducted in which a determined single dose of caffeine and
numerous determined doses of DEX were administered following a dose of
MDMA. The study was conducted with 3 healthy male volunteers and served to
profile the dose of each drug with regards to the intervals of administration
between them.
The design of the study is shown in Figure 3.1. The volunteers participated in 2
sessions, separated by a minimum of 3 days. At the beginning of each session,
subjects arrived at the laboratory at 07.30 h following an overnight fast. An
indwelling intravenous catheter was inserted into a subcutaneous vein in the
forearm of the non-dominant arm and 0.9% sodium chloride solution was infused
at a rate of 20 mL/h. Thereafter, they remained seated in a quiet room throughout
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the session. Drugs were administered at 8:30 AM. A light meal was provided 6 h
after drug administration. In the first session all volunteers received a single 30
mg dose of DEX and a single 100 mg dose of caffeine together with 250 mL of
water. With respect to the safety of DEX, the recommended dose for the
treatment of cough in adults is 15-30 mg for a maximum of 4 times daily. Hence,
the dose administered in this study was less than those used to treat acute cough
and has been used in the past to probe CYP2D6 activity. The dose of caffeine
was equivalent to an intake of 1-1.5 cups of coffee and was not expected to
cause any adverse effects. Urine was collected for 0-8 h and its pH was
measured and subsequently acidified and aliquots were stored at -20°C until
further analysis. Blood samples of 8 mL were collected at 0, 0.5, 1, 2, 4, 6, 8, 10,
12 and 25 h after DEX and caffeine administration. After centrifugation at 4°C,
four 1 mL aliquots of plasma were stored at -20°C for further analysis. Tobacco
smoking was permitted 6 h after drug administration.This session served to
determine basal activities of CYP2D6 and CYP1A2.
From the previous experiences with MDMA at single doses (from 50 to 150 mg),
in combination with ethanol (100 mg), multiple doses (50 to 100 mg), interaction
with paroxetine (100 mg), a single dose of 100 mg clearly inhibits the metabolism
of a subsequent dose of MDMA between 2 and 24 h. A dose of 100 mg produces
Session 1 Session 2




' MDMA ' 30 mg




Figure 3.1. Scheme of the clinical trial to measure the duration of inhibition of CYP2D6 by
MDMA showing dose intervals.
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evident physiological and subjective effects in male subjects between the weights
63 and 82 kg and is not accompanied by relevant adverse effects and has not
caused health and safety problems in a laboratory setting. It was proposed to
administer a single dose of 1.5 mg/kg (maximum dose 100 mg). In this manner, a
participant weighing 50 kg received 75 mg, those weighing 60 kg received 90 mg
and finally those who weigh 66.7 kg or more received a dose of 100 mg. Thus, in
the second session the subjects received a single dose of MDMA together with
250 ml_ of water and a single dose of caffeine four hours later. Repetitive oral
doses of 30 mg DEX were administered at fixed intervals to investigate the
intensity and duration of CYP2D6 inhibition. With respect to the interval between
the doses of DEX, it was initially proposed that in the pilot study, the
administration of DEX should be 30 mg at 4 h, 24 h, 48 h, 96 h and 168 h after
the dose of MDMA. Urine samples were collected from 0-4 h, 4-12 h, 24-32 h, 48-
56 h, 96-104 h, 168-176 h following the administration of MDMA. Blood samples
of 8 mL were collected at 0, 0.5, 1, 2, 4, 6, 8, 10, 12 and 25 h after DEX and
caffeine administration. After centrifugation at 4°C, four 1 mL aliquots of plasma
were stored at -20°C for further analysis. Tobacco smoking was permitted 6 h
after drug administration.
Upon completion of the pilot study it was observed that the MR following the final
dose of DEX (168 h) had not recovered to basal levels. Therefore, the final study
was modified to include a dose of DEX at 240 h following MDMA administration.
Apart from this minor change, no other changes in dose or interval of
administration were affected and the results from the pilot study were added to
the final results.
3.1.2.3. Final phase of study
12 healthy male volunteers were selected. The volunteers participated in 2
sessions separated by a minimum of 3 days. The development of the sessions
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was the same as the pilot trial with the exception that DEX was administered at 4
h, 24 h, 96 h, 168 h and 240 h after the dose of MDMA. The demographics and
history of drug use of the male volunteers that participated in both phases of the

































































































































































































































































Table 3.1.2 Demographics of male volunteers that participated in the study. B.M.I = Body
mass index; GHB = y-hydroxybutiric acid; BDZ = benzodiazepines; AL = Alcohol; CA -
Cannabis; CO = Cocaine; Others = LSD, psychoactive mushrooms; CU = current use; N = no



































































































































Table 3.1.3 DEX phenotype and genotype of cytochrome P450 enzymes involved in MDMA
and DEX metabolism of male volunteers who participated in the study.
3.2. Validation of analytical methods
In preparation for the analysis of the samples generated from the clinical trial,
methods for the quantification of the markers of CYP activity were validated. A
calibration curve was chosen which represented the expected concentrations
range of each analyte. Each analytical procedure was validated following the
conduction of four assays (table 3.2.1). The first assay was conducted to
calculate the limits of detection, limits of quantification, recovery as well as the
linearity of the calibration curve. The second was carried out to monitor the
stability of freeze/thaw actions on the analyte. The third monitored contamination
between samples and the fourth checked for stability in case of dilution of the
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Table 3.2.1 Scheme of validation procedure for quantification of substances in biological
matrices. CI = inferior control; CM = medium control; CS = superior control; M = Matrix; W =
Without Matrix; F/T = Freeze/Thaw cycles; V = volume; Vr = reduced volume, assay volume
divided by 2.
3.2.1. Validation of the quantification of DEX and metabolites in
plasma and urine
Standard solutions of 1000 mg/L DEX and metabolites and internal standard
(levalorphan) were prepared in methanol. Serial dilutions were then made of each
standard solution for final concentrations of 100, 10 and 1 mg/L. Concentrations
of standard solutions were confirmed by UV spectroscopy. The concentrations of
the calibrators for each analyte were 40, 250, 500, 800 and 2000 u.g/L for DEX,
DOR, MM and HM in urine and 10, 50, 100, 200 and 300 ^g/L for DEX, DOR,
MM and HM in plasma. Controls had a concentration of 60, 400 and 1000 \iglL in
urine and 20,125 and 250 |ig/L in plasma.
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Aliquots of urine and plasma were analyzed by HPLC/FLD using levalorphan as
an internal standard. Samples were hydrolyzed for 3 h at 55°C or overnight at
37°C using 1 mL ß-glucuronidase solution (Type H-1 from Helix pomatia) in 0.1 M
sodium citrate (pH 5.0). Extraction was carried out after the addition of 1 mL
(NH4CI/NH3 (pH 9.5) on mixed-mode solid reversed phase columns (Bond Elut
Certify™, Varian, Palo Alto, CA, USA) pre-conditioned with 2 mL methanol and 2
mL H2O. Columns were then washed with 2 mL H2O (MilliQ, ultrapure), 1 mL 1 M
acetic acid and 2 mL methanol. Columns were dried for 10 min at room
temperature and analytes are eluted with 2 mL chloroform:isopropanol 80:20,
ammonium hydroxide 2%. The eluent was dried at 40°C under a nitrogen stream
for 20 min (Turbovap®, Zymark®, Kopkinton, MA, USA). Samples were
reconstituted in 100 nL mobile phase and 15 ^L (urine) and 25 \iL (plasma) were
injected into the Chromatographie system.
Chromatographie separation was carried out on an Ultrasphere ODS (4,6 cm x
7.5 cm x 3 îm) (Beckman Coulter ™, Palo Alto, USA) connected to a 1090 II high
performance liquid Chromatograph (Hewlett Packard, Palo Alto, CA) coupled to a
fluorescent detector model 1100 at excitation and emission wavelengths of 280
and 310 nm, respectively. The mobile phase used was acetonitrile: 22 mM
sodium acetate buffer, 0.05% TEA (pH 3.3) (20:80, v/v) applied as an ¡socràtic
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Figure 3.2. Chromatogram of dextromethorphan and metabolites analysis by HPLC/FLD. 1. =
dextrorphan; 2. = hydroxymorphinan; 3. = levalorphan (internal standard); 4. =
dextromethorphan; 5. = methoxymorphlnan.
A chromatogram showing the retention times of DEX and metabolites is shown in
Figure 3.2. Calibration curves for the HPLC method were linear over the chosen
concentration ranges for DEX, DOR, MM and HM. Peak ratios between
compounds and internal standard were used for calculations. A weighted
(1/concentration) least square regression analysis was used (SPSS for Windows,
version 12.0). Recovery was >70% for all compounds. Mean determination
coefficients were 0.994 ± 0.002 for DEX, 0.991 ± 0.002 for DOR, 0.992 ± 0.002
for MM, and 0.991 ± 0.001 for HM. In urine, the inter-assay precision and
accuracy were 11.4% and 10.1% for DEX, 9.1% and 8.5% for DOR, 11.9% and
12.3% for MM and 12.0 and 9.0% for HM with limits of detection of 13 |ig/L, 7
|ig/L, 12 ^g/L and 13 ng/L for DEX, DOR, MM and HM, respectively. In plasma,
the inter-assay precision and accuracy was 14.6% and 12.3% for DEX, 12.0%
and 9.5% for DOR, 15.0% and 12.6% for MM and 10.2% and 11.8% for HM with
limits of detection of 1.5 |ig/L, 2.5 ng/L, 1.5 (ig/L and 4.0 ^g/L for DEX, DOR, MM
and HM respectively. No cross-contamination of samples was observed in the
chromatograms of various blank samples. The assay was stable to a dilution













Figure 3.3 Chromatogram of caffeine and metabolites analysis by HPLC/UV. 1.
(caffeine); 2. = 17X (paraxanthine); 3. = 1X (1-methyl xanthine); 4. = 17U (1,7-dimethyluric
acid); 5. = AAMU (5-acetylamino-6-amino-3-methyluracM); 6 = 1U (1-methyluric acid); 7 = 9U
(9-methyluric acid, internal standard).
3.2.2. Validation of the quantification of caffeine and metabolites in
urine
Standard solutions of 1000 mg/L of caffeine (137X), paraxanthine (17X), 1-
methylxathine (1X), 1-methyluric acid (1U), 1,7-methyluric acid (17U), 5-
acetylamino-6-amino-3-methyluracil (AAMU) and internal standard, 9-methyluric
acid (9U) were prepared in water or 10 mM sodium hydroxide. Serial dilutions
were then made of each standard solution for final concentrations of 100,
1 mg/L. Concentrations of standard solutions were checked by UV spectroscopy.
The concentrations of the calibrators for each analyte were 2, 10, 20, :
mg/L for 137X, 17X, 1X, 1U, 17U and AAMU. Controls had a concentration of í
15 and 40 mg/L.
Caffeine and metabolites were analysed in urine by a modified procedure
previously published168. Briefly, 30 Hl of 0.5M NaOH is added to 150 jil aliquots of
urine and vortexed. The solution is left at RT for 30 min to oxidise AFMU to
AAMU and then 40 nl of 0.5 M MCI is then added followed by 50 ML of internal
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standard. The solution is vortexed for 30 s. 100 p.! dimethylfluorene:ethylacetate
(30:70) is added followed by 800 jJ acetonitrile. The mixture is vortexed for 30 s
and centrifuged at 10,000 g for 10 min. 25 (il is injected into the Chromatographie
system.
Chromatographie analysis was carried out using a 1090 II high performance
liquid Chromatograph (Hewlett Packard, Palo Alto, CA) coupled to a UV model
1100 at 260nm and 280nm. The mobile phase used was acetonitrile: 0.7% formic
acid (91:9, v/v) applied as an ¡socràtic gradient with a flow rate of 1 mL/min for a
run of 62 min. The HPLC column used was a Grom-sil 120 (4.6cm x 25cm x 5
um) (GROMAnalytik, Rottenburg-Hailfingen, Germany).
A chromatogram showing the retention times of 137X and metabolites is shown
in Figure 3.3. Calibration curves for the HPLC method were linear over the
chosen concentration ranges for 137X, 17X, 1X, 1U, 17U and AAMU. Peak ratios
between compounds and internal standard were used for calculations. A
weighted (1/concentration) least square regression analysis was used (SPSS for
Windows, version 12.0). Since the procedure was extractionless recovery was
considered to be 100% for all compounds. Peak ratios between compounds and
internal standard were used for calculations. Mean determination coefficients
were 0.999 ± 0.001 for 137X, 0.999 ± 0.001 for 17X, 0.998 ± 0.001 for 1X, 0.998
± 0.001 for 17U, 0.999 ± 0.002 for AAMU and 0.998 ± 0.002 for 1U. Limits of
detection and quantification as well as inter-assay precision and accuracy are
shown in table 3.2.2. No contamination of samples was observed in the
chromatograms of various blank samples. The assay was stable to a dilution











































Table 3.2.2 Limits of detection and quantification for caffeine and metabolites in urine. 137X
= 1,3,7-trimethylxanthine (caffeine); 17X = 1,7-dimethylxanthine (paraxanthine); 1X = 1-
methylxanthine; 17U = 1,7-dimethyluric acid; AAMU = 5-acetylamino-6-amino-3-methyluracil;
1U = 1-methyluric acid. * Relative Standard Deviation of the control samples.
3.2.3. Validation of the quantification of caffeine and paraxanthine in
plasma
Standard solutions of 1000 mg/L of caffeine (137X) and paraxanthine (17X) were
prepared in water, and internal standard diphylline in methanol. Serial dilutions
were then made of each standard solution for final concentrations of, 100, 10 and
1 mg/L. Concentrations of standard solutions were checked by UV spectroscopy.
The concentrations of the calibrators for each analyte were 50, 200, 500, 1000
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Figure 3.4. Chromatogram of caffeine and paraxanthine analysis by HPLC/UV. 1. = 17X
(paraxanthine); 2. = diphyline (internal standard); 3. = 137X (caffeine).
Caffeine and paraxanthine are extracted from 500 ml_ of plasma using a
liquid/liquid extraction procedure by adding 4 ml_ of ethylacetate and 200 mg of
potassium sulphate. The mixture was vortexed for 30 s. Samples were agitated
for 20 min and then centrifuged at RT for 5 min. The organic layer was separated
and evaporated to dryness at RT at 40°C using a gentle stream of nitrogen
(Turbovap®, Zymark®, Kopkinton, MA, USA). The residue was reconstituted in
100 fil mobile phase and 25 (il was injected into the HPLC system.
Chromatographie analysis was carried out using a 1090 II high performance
liquid Chromatograph (Hewlett Packard, Palo Alto, CA) coupled to a UV model
1100 at 274 nm. The mobile phase used was acetonitrile: acetic acid (0.05%)
(99:1, v/v) applied as an ¡socràtic gradient with a flow rate of 1 mL/min for a run of
15 min. The HPLC column used was an Ultrasphere ODS (4.6cm x 7.5cm x 3 ^l)
(Beckman Coulter ™, Palo Alto, USA).
A chromatogram showing the retention times of 137X and 17X is shown in figure
3.4. Calibration curves for the HPLC method were linear over the chosen
concentration ranges for 137X and 17X. Peak ratios between compounds and
internal standard were used for calculations. A weighted (1/concentration) least
square regression analysis was used (SPSS for Windows, version 12.0).
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Recovery was 100% for 137X and 93% for 17X. Mean determination coefficients
were 0.994 ± 0.003 for 137X and 0.997 ± 0.001 for 17X. Limits of detection were
3 ng/L and 12 |ig/L for 137X and 17X respectively. Inter-assay precision and
accuracy were 10.0% and 7.8% for 137X and 4.2% and 5.9% for 17X. No
contamination of samples was observed in the chromatograms of various blank
samples. The assay was stable to a dilution factor of two and up to two freeze
and thaw actions for all compounds in both plasma and urine.
3.3. Animal Studies
3.3.1. Animals and MDMA treatments
In all cases, the doses of MDMA used refer to the hydrochloride salt. All the
procedures followed in the present work were in compliance with the European
Community Council Directive (86/609/EEC) and were approved by an Ethical
Committee.
3.3.1.1. COMT inhibition and MDMA-induced hyperthermia and metabolism
Male Wistar rats (290-340 g) were housed in plastic cages in a temperature
controlled room (21.5 ± 1° C) with free access to food and water and maintained
on a 12/12 h light/dark cycle (lights on at 07.00 h). Three sets of experiments
were performed:
JL Sa//ne or the catechol-O-methyltransferase (COMT) inhibitor entacaoone (30
mal kg i.p.) was administered 30 min before MDMA (3x5 mal ko i.o.) in order to
prevent the O-methvlation of HHMA or HHA. Rats were sacrificed 1 h after
MDMA administration for the measurement of MDMA, its metabolites, including
HHMA and HHA, and serum concentrations of L-tyrosine. In parallel, a different
batch of rats was sacrificed one week after MDMA to measure brain índole
content. The dose of entacapone was chosen based on previous findings
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indicating that rat liver COMT activity is completely inhibited 30 min after injection
and remains reasonably inhibited (-75%) six hours later169.
entacapone
2. To ascertain the influence of different ambient temperatures on MDMA
metabolism and long-term neurotoxicitv. Rats were treated intraperitoneally with
either saline or MDMA (final dose equivalent to 15 mg/kg) with two different
dosing regimens: 1 x 15 mg/kg; or 3 x 5 mg/kg every 2 hours at ambient
temperatures of 15, 21.5 or 30 ± 1°C. Trunk blood was withdrawn by saphenous
vein puncture to measure plasma concentrations of MDMA and its main
metabolites at different time points. Rats were sacrificed at 1 week and brain
Índole content was measured.
3. The effect of direct application of MDMA into the striatum or entacapone into
the hippocampus in combination with a toxic dosage regimen of MDMA (3x5
mo//eg ¡.p., given 2 h apart) was assessed. For this, 12 h before dialysis
experiments the obturators were removed from the guide cannulae and a
microdialysis probe (CMA/11) was inserted slowly through each cannula into the
brain of the awakened rat such that the membrane protruded its full length (4
mm) from the end of the probe. The probes were connected via spring-covered
FEP-tubing (CMA, Sweden) to a dual channel swivel (Instech, Plymouth Meeting,
PA, USA) that allowed for relatively unrestrained movement of the animal. Probes
were perfused overnight with artificial cerebrospinal fluid (aCSF; NaCI: 120 mM;
KCI: 1.4 mM; CaCI2: 1.2 mM; MgCI2: 0.83 mM and D-glucose 10 mM pH 7.4) at a
flow rate of 1 (il/min. In the following morning, fresh aCSF was perfused at a flow
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rate of 2 ¡al/min for an additional 1,5 h equilibration period. The perfusion medium
of the probe of each animal was then switched to one containing MDMA (100
nM) or entacapone (100 jiM). At this time point rats also received the first of three
injections of saline or MDMA (5 mg/kg i.p.) given every 2 h. The perfusion
continued for an additional 5 h in the case of MDMA or 2 h in the case of
entacapone. The concentration of MDMA in the perfusate was chosen based
upon previous studies showing that the extracellular concentration of MDMA
under these experimental conditions is similar to that found after systemic
neurotoxic doses of MDMA100'119'170. On the other hand, the concentration of
entacapone in the perfusate was chosen based upon a previous study showing
an effective inhibition of brain COMT activity171.
Seven days after reverse dialysis experiments were completed, animals were
sacrificed by decapitation, their brains were rapidly removed and one 1 mm thick
tissue section was taken (approximately 0.5 mm to either side of the probe).
Striatal tissue was dissected out from the side where the probe was implanted
and 5-HT, dopamine and their respective metabolites were quantified using
HPLC-ED.
3.3.1.2. The role of L-tyrosine in the development of MDMA-induced
neurotoxicity in rats
Male Wistar rats (290-340 g) were housed in plastic cages in a temperature
controlled room (21.5 ± 1° C) with free access to food and water and maintained
on a 12/12 h light/dark cycle (lights on at 07.00 h). Three sets of experiments
were performed:
L-Rats were /reateç/ jntraperitoneallv with saline, a toxic dose of MDMA (15
0231kg /.D.) or a nnn.tpxic dose of MDMA (7.5 mg//cq). In this case, hyperthermia,
serum tyrosine levels, metabolic disposition of MDMA and long-term 5-HT
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depletions were compared among groups. All the parameters analyzed differed
between both doses of MDMA. For this reason, using the non-toxic dosing
regimen of MDMA different experiments were performed aimed at modifying
serum tyrosine levels and/or MDMA metabolic disposition to ascertain the real
contribution of both factors in the mechanism underlying MDMA-induced 5-HT
neurotoxicity. Accordingly, MDMA was administered alone or in combination with
L-tyrosine methylester-HCI (equivalent to 0.2 or 0.5 mM/kg free L-tyrosine). The
tyrosine/MDMA combination was given in one sole intraperitoneal injection at a
standard ambient temperature (21.5±1°C), or at a low ambient temperature
(15±1°C) to reduce the metabolic rate of MDMA. In one experiment rats were
also treated with a non-toxic dose of MDMA and had their rectal temperature kept
elevated to near that seen in rats given a toxic ¡ntraperitoneal injection of MDMA
(15 mg/kg). This was achieved by placing the rats in a cage with a homeothermic
blanket (Homeothermic System HB121S402, Panlab, Spain) covering the base.
The blankets were switched on 2 hours after the administration of the non-toxic
dose of MDMA (once the hyperthermia of the animals started to decrease) and
were turned off six hours later so that rats were kept hyperthermic for 8 hours. In
this experiment, control animals were heated 1 h before saline injection to cause
an overall increase in body temperature similar to that found in the MDMA-treated
group.
2. The effect of direct application of MDMA into the striatum in combination with
an injection oftyrosine (0.5 mmol/kg) was assessed. For this, 12 h before dialysis
experiments the obturators were removed from the guide cannulae and a
microdialysis probe (membrane length: 4.0 mm x 240 urn; CMA/11, Sweden) was
inserted slowly through each guide cannula into the striatum of the awake rat
such that the membrane protruded its full length from the end of the probe. The
probes were connected via spring-covered FEP-tubing (CMA, Sweden) to a dual
channel swivel (Instech, Plymouth Meeting, PA, USA) that allowed for relatively
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unrestrained movement of the animal. Probes were perfused overnight with
artificial cerebrospinal fluid (aCSF; NaCI: 125 mM; KCI: 2.1 mM; CaCI2: 1.2 mM;
MgCI2: 1.2 mM and D-glucose 0.5 mM pH 7.4) at a flow rate of 1 uL/min. On the
following morning, the flow rate was increased to 2 uL/min for an additional 1.5 h
equilibration period. The perfusion medium of the probe of each animal was then
switched to aCSF containing MDMA (100 uM). At this time point rats received an
injection of saline or tyrosine (0.5 mmol/kg ¡.p.). The perfusion continued for an
additional 5 h. In these experiments, rats had their rectal temperature kept
elevated for 8 hours according to the procedure described above. Seven days
after reverse dialysis experiments were completed, animals were killed by
decapitation their brains were rapidly removed and one 1-mm thick tissue section
was taken (approximately 0.5 mm to either side of the probe).
.3. The catechol-O-methvl transferase (COMT) inhibitor entacapone (30 mq//cq
i.D.) was given 30 min before a single injection of MDMA (7.5 mal kg i.p). The
dose of entacapone was chosen based on previous findings indicating that rat
liver COMT activity is completely inhibited 30 min after injection and remains
reasonably inhibited (-75%) six hours later169.
3.3.2. Surgical procedures
Rats were anaesthetized with a combination of ketamine (70 mg/kg i.p.) and
xylazine (7 mg/kg i.p.) and placed in a Kopf stereotaxic frame, with the incisor bar
set at 3.3 mm below the interaural line. The skull was exposed, and holes were
drilled to allow implantation of a guide cannula (CMA/11, Sweden) into the right
striaturn (0.2 mm anterior, 3.0 mm lateral from bregma) or the right ventral
hippocampus (5.6 mm posterior, 5.0 mm lateral from bregma)172. The guide
cannulae were secured to the skull with two bone screws, cyanoacrylate glue and
dental acrylic cement. After surgery, the animals were housed individually with
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free access to food and water. The rats were allowed to recover from surgery,
and the reverse dialysis experiments were carried out 4-5 days later.
Seven days after reverse dialysis experiments were completed, animals were
sacrificed by decapitation, their brains were rapidly removed and one 1 mm thick
tissue section was taken (approximately 0.5 mm to either side of the probe).
Striatal tissue was dissected out from the side where the probe was implanted
and 5-HT, dopamine and their respective metabolites were quantified using
HPLC-ED. In all cases samples were frozen in dry ice and stored at -80°C until
analysis.
3.3.3. Temperature measurements
Rectal temperature of the rats was measured at an ambient temperatures of 15,
21.5 or 30 ± 1°C with a lubricated digital thermometer probe (pb 0331, Panlab,
Barcelona) inserted 3 cm into the rectum, the rat being lightly restrained by hand.
Rats were exposed to low (15°C) or high (30°C) ambient temperatures from 60
min prior to the first MDMA administration up to one hour after the last rectal
temperature measurement. At this time point, rats were put back in the colony
room set at ambient temperature of 21.5 ± 1°C. Temperature was recorded
before any MDMA treatment and thereafter every 60 min up to 6 or 8 h. Probes
were re-inserted from time to time until the temperature stabilized.
3.3.4. Blood Sampling
In the experiments pertaining to metabolism and hyperthermia, rats were
separated in two different groups. In one group blood was withdrawn at 1, 3 and
5 h while in the other group of animals blood was withdrawn at 2, 4 and 6 h after




Saphenous vein puncture for blood sampling was used as previously
described173. Blood drops were collected into Microvette® CB 300LH tubes and
centrifuged immediately. After centrifugation, plasma was transferred to sterile
Eppendorf tubes containing metabisulphite (2 ^L, 0.001% w/v). Samples were
frozen and stored at -20°C until analysis.
3.3.5. Pharmacokinetic analysis
MDMA, MDA, HMMA and HMA concentrations in plasma were determined
following a previously described method174. Briefly, aliquots of 100 uL of plasma
were hydrolyzed enzymatically with ß-glucuronidase at pH 5.2 (incubation for 16
h at 37°C). After hydrolysis, samples were adjusted to pH 6 and a solid-phase
extraction using mixed-mode solid reversed phase columns (Bond Elut Certify™,
Varian, Palo Alto, CÂ, USA) was carried out. The extracts were evaporated to
dryness (40°C) and the dried extracts were derivatized with 50 uL of MBTFA for
45 min at 70°C. Once cooled, the samples were transferred to autosampler vials
and analyzed using gas chromatography-mass spectrometry (GC-MS, MSD5973,
Agilent, Palo Alto, CA).
The presence of HHMA and HHA in plasma was determined by using a
previously published method175. An acidic hydrolysis was performed before a
solid-liquid extraction using strong cation exchange (SCX, Varian, Palo Alto, CA,
USA) columns followed by HPLC-ED.
Serum L-tyrosine concentrations were measured by HPLC-ED as previously
described by Bongiovanni et al.176 with minor modifications. Briefly, the HPLC
system consisted of a Waters Spherisorb ODS2 column 4.6 x 150 mm (Waters,
Milford, Massachusetts, USA), an ED operated at a relative potential of 0.75 V to
a Ag/AgCI reference electrode. The mobile phase consisted of 75% aqueous
0.133 mM Na2HPO4 and 25% methanol adjusted to pH 6.8 with o-phosphoric
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acid. Serum (50 uL) was added to a series of 1.5 ml_ Eppendorf tubes followed
by 450 uL of ice-cold ethanol containing 20 nmol/mL of norvaline (internal
standard). Samples were then vortexed for 30 s and centrifuged for 45 min at
8000 x g. To detect tyrosine, a derivatizing agent was used (OPA-S; 10 mg o-
phthaldehyde and 30 mg sodium sulphite diluted to 5.0 mL with 0.1 M sodium
carbonate pH 10.4) for the reaction media. To a series of 1.5 mL Eppendorf tubes
was added 10 uL of sample, standards (1.25-20 nmol/mL) or blanks, and 5 uL
OPA-S, reacted for 5 min and brought to a final volume of 100 uL with HPLC
mobile phase. A 20 uL sample was injected onto the column. Data for L-tyrosine
is presented in nmol/mL.
3.3.6. Neurochemical measurements
Concentrations of 5-HT, 5-HIAA, DA, DOPAC and HVA in the brain regions of the
rats were determined by high performance liquid chromatography with
electrochemical detection (HPLC-ED) as previously described10.
It has been recently suggested that measurement of tissue 5-HT concentration
may overestimate neurotoxic damage caused by MDMA. For this reason
[3H]paroxetine binding studies to the 5-HT transporter were performed according
to the procedure described by Aguirre et al.177. These experiments were only




Values of the maximum plasma concentration (Cmax) and the time to reach
Cmax (tmax) were noted directly from the plasma concentration - time profiles of
DEX, DOR, MM and HM. Area under curve values (AUC(0,t) were determined
from 0-8 h (session 1 data) and 4-12 h (session 2 data) using the trapezoidal
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rule. Elimination rate constants (k) were estimated by log-linear regression of
terminal data points. Values of pharmacokinetic parameters were compared
between sessions by the paired Student t test (Cmax and AUC) and the Wilcoxon
test (tmax). Differences were considered to be significant at p < 0.05.
Relationships between urinary DEX/DOR metabolic ratio (MR) and
Cmax;DEX/Cmax;DOR, MR and urine pH, and MR and urine creatinine
concentration were assessed by the Pearson correlation coefficient. The fold-
change in MR values at the mean of each urine sample period in session 2
relative to the MR value in session 1 were plotted against time after MDMA
dosage for each volunteer. A monoexponential equation was fitted to the
individual profiles by non-linear regression, with weighting by the standard
deviation of the MR in the respective urine sampling interval, to estimate a value
of CYP2D6 recovery half-life (In(2)/Kcyp):
A(t)=A1e"
Kcypt
Where A(t) is the fold change in DEX urinary MR following MDMA administration
expressed by MRinh/MRControi at the mid-point of time interval t, A(0) is the baseline
value, and Kcyp is the first-order rate constant for CYP2D6 recovery. Goodness of
fit of each equation to the observed values was evaluated by visual examination





Equations were fitted to observed data by minimising the weighted sum of the
squares through change of the parameters A and K^p in the above equations
using the Newton method in the "Solver" tool in Excel®, Microsoft (1000
iterations, tolerance of 1%, precision of 1 x 10"6 and convergence of 1 x IÓ"4).
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Weighted sum of the squares (WSS) were calculated for the model by the
following equation:
t=n
y(Y/ j \ observed,!
t=1
-Y i- w' predicted,! / v v i
Where t is the urine recovery time interval, n is the number of intervals and W¡ is
the standard deviation of A (MRSession2,t/MRsession 1) at time interval f.
The goodness of fit of each equation to the observed values was evaluated by
Akaike's Information Criterion (AIC) whereby:
AIC = N-ln(WSS) + 2-M
Where A/ is the number of data points and M is the number of parameters.
Goodness of fit was also assessed visually by plotting observed versus predicted
values and time interval versus residuals.
A degradation constant Kdeg of CYP2D6 was calculated as described
previously139. The half-life of return of CYP2D6 activity to baseline should reflect
the CYP2D6 turnover half-life and MDMA steady-state half-life. The CYP2D6
turnover half-life was thus determined using a non-compartmental deconvolution
of the mean residence time of MDMA (1/Ke) from the mean time of return of
CYP2D6 activity to baseline (1/Kcyp) giving a mean CYP2D6 degradation time
(CYP2D6MD-r), first-order degradation rate constant Kdeg (1/CYP2D6MDT) and
degradation half-life (In(2)/Kdeg).
3.4.2. Animal Studies
Time course of temperature changes was analyzed by two-way ANOVA for
repeated measures. Treatment was used as the between-subjects factor and
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time as the repeated measure. Temperature measures were also converted to a
composite measure (TAUC) as previously described by178. The TAUC was
calculated for each rat by the application of Simpson's Rule to temperatures
measured at times -30 min and every hour up 6 or 8 h following MDMA
administration. This composite measure represents the area under the curve of a
plot of temperature (°C) versus time (h), and has units of °C x h. Differences in
TAUC and biochemical concentrations were analyzed either by unpaired Student
t-test or one-way ANOVA. Multiple pair wise comparisons were performed using
the Tukey's test. Differences in MDMA and metabolites, brain monoamine
concentrations and 5-HT transporter density (Bmax) were analyzed either by
unpaired Student t-test or one-way ANOVA. Treatment differences were
considered statistically significant at p < 0.05. Data analyses were performed
using the Statistical Program for the Social Sciences (SPSS for Windows, 11.0).
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ecstasy) is a widely abused substituted
amphetamine. Although there is a growing
consensus that MDMA is toxic in humans, the
mechanisms underlying its toxic effects remain
to be elucidated. MDMA systemic metabolism
has been postulated as a major contributing
factor to drug neurotoxicity[l]. The majority of
MDMA hepatic metabolism in humans occurs
via the O-demethylenation route and is carried
out by isoforms of cytochrome P450 forming
3,4-dihydroxymethamphetamine (HHMA). The
minor active N-demethylated MDMA metabolite
MDA (3,4-methylenedioxyamphetamine), is also
O-demethylenated giving rise to 3,4-
dihydroxyamphetamine (HHA). The O-
demethylenation step in vitro shows biphasic
kinetics with a high and a low affinity
component. The high affinity component is
regulated mainly by the cytochrome P450 2D6
isoenzyme (CYP2D6) and the low affinity
component is regulated by CYP1A2 and to a
lower extent by CYP2B6 and CYP3A4[2]. Both
HHMA and HHA are subsequently O-
methylated by the enzyme catechol-O-
methyltransferase (COMT) mainly to 4-hydroxy-
3-methoxy-methamphetamine (HMMA) and 4-
hydroxy-3-methoxy-amphetamine (HMA),
respectively. These metabolites are known to be
excreted in the urine as glucuronide or sulfate
conjugates[3].
It has been observed in vivo that MDMA inhibits
its own metabolism[4]. This is due to the quasi-
irreversible mechanism based inhibition (MBI)
of CYP2D6 [5;6]. Hence, a short time following
the administration of MDMA the high affinity
component of its first pass metabolism is
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completely and irreversibly inhibited and the
demethylenation of the drug is entirely
dependent on the activities of the enzymes
involved in the low affinity component, in part
regulated by CYP1A2. If MDMA oxidative
metabolism contributes to neurotoxicity then it
would be prudent therefore to study the in vivo
activity of CYP1A2 after CYP2D6 has been
inhibited by MDMA.
CYP1A2 is involved in the activation of
environmental procarcinogens, such as
arylamines, heterocyclic amines, and aflatoxin
Bl and its activity is considerably increased by
xenobiotics, including cigarette smoke[7]. It has
been observed that the methylenedioxy
compound isosafrole inhibits CYP1A2[8] and
methylenedioxy compounds have also been
known to induce cytochrome P450 activity,
including that of CYP1 A2[9]. The mechanism of
induction is thought to follow a binding of the
compound to the aryl hydrocarbon (Ah) receptor
which upon accumulation in the cell nucleus as a
heterodimeric complex acts as a ligand-induced
transcription factor resulting in an increase in
protein expression. On the other hand, evidences
suggest that rat CYP1 Al regulation is modulated
by a protein kinase C and that a phosphorylation
cascade mechanism that activates the Ah
receptor may be involved[10]. Indeed, MDMA
has been shown to activate protein kinase C
within synaptic terminals[l 1]. Hence, there is
reason to hypothesize that CYP1A2 could be
modulated by MDMA. This would have
consequences for both MDMA pharmacokinetics
and toxicity and that of other CYP1A2
substrates.
Caffeine is well known as a metabolic probe for
CYP1A2[12] and it has a high margin of safety.
It has been used extensively in the past to
investigate gender and age differences in
CYP1A2 activity[13;14] and changes in activity
due to medication, smoking and diet[7;15;16].
Although CYP2E1, CYP2A6 and CYP3A4 are
involved in caffeine metabolism, 90% of its
clearance is thought to be controlled by
CYP1A2. Its clearance in plasma is considered
the "gold standard" for the measurement of
CYP1A2 activity in humans. At least six
different urinary metabolic ratios for caffeine
have been proposed as in vivo probes for
CYP1A2 activity and of these the ratio
(AAMU+1X+1U)/17U seems to be the most
robust seeing as it is the most sensitive to
changes in CYP1A2 activity and not affected as
much by other enzyme activities or urine
flow[12].
In an attempt to monitor the activity of CYP1A2
following a recreational dose of MDMA a
clinical trial was designed whereby caffeine
pharmacokinetics and urinary metabolic ratios
were measured in subjects who had previously
been administered MDMA.
MATERIALS AND METHODS
The study was conducted in accordance with the
Declaration of Helsinki, approved by the local
Institutional Review Board (CEIC-IMAS), and
authorized by the Dirección General de Farmacia
y Productos Sanitarios (98/112) of the Spanish
Ministry of Health. All volunteers gave their
written informed consent before inclusion in the
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study and were compensated for their
participation in the experimental sessions.
Volunteers were recruited by word of mouth.
Eligibility criteria required the recreational use
of MDMA on at least ten occasions and twice in
the previous year. Each eligible subject was
initially interviewed by a physician to exclude
concomitant medical conditions, and underwent
a general physical examination, routine
laboratory tests, urinalysis, and 12-lead ECG.
Volunteers who fulfilled the inclusion criteria
were then interviewed by a psychiatrist
(Psychiatric Research Interview for Substance
and Mental Disorders for DSM-IV, PRISM-IV)
to exclude individuals with history or actual
major psychiatric disorders (schizophrenia,
psychosis, and major affective disorder) (21).
Volunteers had a mean age of 26 years (range
19-33), mean body weight of 69.6 Kg (range
54.2-91.2), and mean height of 181 cm (range
171-196). They referred an average of 26
previous experiences (range 6-100) with
MDMA. All but four subjects were current
smokers. None met criteria of abuse or drug
dependence (except for nicotine dependence).
All had previous experience with other
psychostimulants, cannabis or hallucinogens.
None had history of adverse medical or
psychiatric reactions after MDMA consumption.
The design of the study has been published
previously! 17]. Briefly, in the first session of the
study subjected received 100 mg caffeine
anhydride together with 30 mg
dextromethorphan orally. Blood and urine
samples were taken over 24 hours to determine
the concentrations of caffeine, dextromethorphan
and their respective metabolites (control). In a
second session subjects were administered a 1.5
mg/kg oral dose of MDMA and four hours later
100 mg caffeine anhydride together with 30 mg
dextromethorphan (active).
At the beginning of each session, subjects
arrived at the laboratory at 07,30 h following an
overnight fast. An indwelling intravenous
catheter was inserted into a subcutaneous vein in
the forearm of the non-dominant arm and 0.9%
sodium chloride solution was infused at a rate of
20 mL/h. Thereafter, they remained seated in a
quiet room throughout the session. Drugs were
administered at 8:30 AM (dextromethorphan and
caffeine in session 1 and MDMA in session 2).
A light meal was provided 6 h after drug
administration. Urine was collected for 0-8 h in
session 1 following caffeine administration and
4-12 h in session 2 following MDMA
administration. Urine pH was measured and
subsequently acidified and aliquots were stored
at -20°C until further analysis. Blood samples of
8 mL were collected at 0, 0.5, 1, 2, 4, 6, 8, 10, 12
and 25 h after caffeine administration in session
1 and at 0, 0.5, 1, 2, 4, 4.5, 5, 6, 8, 10, 12, 25 h
after MDMA administration in session 2. After
centrifugation at 4°C, four 1 mL aliquots of
plasma were stored at -20°C for further analysis.
Tobacco smoking was permitted 6 h after drug
administration. Subjects were requested to
refrain from consuming any drug two weeks
before and throughout the duration of the study
and asked to follow a xanthine free diet 48 h
before the beginning of each session. At each
session and before drug administration, urine
samples were collected to check for the use of
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drugs of abuse (opiates, cocaine metabolite,
amphetamines, and eannabinoids) by
immunological methods (FPIA, Abbott
Laboratories, Chicago, IL, USA).
Caffeine and paraxanthine are extracted from 500
mL of plasma using a liquid/liquid extraction
procedure. 4 mL of ethylacetate and 200 ¡iL of
saturated potassium sulfate are added to 500 uL
of plasma. The mixture was vortexed for 30 s.
Samples are agitated for 20 min and then
centrifuged room temperature for 5 min. The
organic layer was separated and evaporated to
dryness at 40°C using a gentle stream of nitrogen
(Turbovap®, Zymark®, Kopkinton, MA, USA).
The residue was reconstituted in 100 jaL mobile
phase and 25 ^L were injected into the HPLC
system. Chromatographie analysis was carried
out using a 1090 II high performance liquid
Chromatograph (Hewlett Packard, Palo Alto, CA)
coupled to a UV model 1100 at 274nm. The
mobile phase used was acetonitrile: acetic acid
(0.05%) (99:1, v/v) applied as an ¡socràtic
gradient with a flow rate of 1 mL/min for a run of
15 min. The HPLC column used was an
Ultrasphere ODS (4.6cm x 7.5cm x 3|jL)
(Beckman Coulter ™, Palo Alto, USA). The
inter-assay precision and accuracy was 10.0% and
7.8% for caffeine and 4.2% and 5.9% for
paraxathine with limits of detection of 3.5 ug/L
and 12 pg/L for caffeine and paraxanthine
respectively. Caffeine (137X), paraxanthine,
(17X), 1-methylxanthine (IX), 1,7-dimethyluric
acid (17U), 1-rnethyluric acid (1U) and 5-
acetylamino-6-amino-3-methyluracil (AAMU)
were analyzed in urine by a previously published
procedure[18]. The procedure was validated in
our laboratory giving an inter-assay precision and
accuracy of less than 7.0% and 10.0% for all
analytes with limits of detection less than 1.5
Hg/mL.
For caffeine and paraxanthine plasma
concentrations, peak concentration (Cmax), time
to reach peak concentration (t^*) and area under
the concentration-time curve from 0-8 h and 0-
21 h in session 1 and 4-12 h and 4-25 h in
session 2 in session 2 (AUCgi,; AUC2]h) were
calculated. The AUC values were calculated by
the trapezoidal rule. The elimination rate
constant for caffeine and paraxanthine was
calculated by log-linear regression and converted
to half-life of elimination (t'/2e)- AUC's were
brought to infinity and the systemic oral
clearance (C10) was calculated by dividing the
dose in mg/Kg body weight by AUC2ih- The
following urinary metabolic ratios were




Values for urinary metabolic ratios and caffeine
and paraxanthine pharmacokinetics in session 1
and session 2 were compared using a paired
Student's t test (MR's, Cmax, AUC, t'/2e and C10)
and the Wilcoxon test for non-parametric values
(!„!„). Differences associated with p values lower
than 0.05 were considered to be statistically
significant. Spearman correlations were also
carried out for the following variables in the
current population: urinary metabolic ratio (MR)
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versus caffeine AUC8h and the ratio of 17X to
137X plasma concentrations at 8 h.
TABLE 1. Caffeine and paraxathine
pharmacokinetics before (session 1) and
after (session 2) a 1.5 mg/Kg oral dose of
































































bAUC values in session J refer lo 0-8 h and in session 2
refer to 4-12H
'Paraxathine and caffeine plasma concentrations at 8 h
post MDMA dose
*p < 0.05 by paired Student t-test
RESULTS
Caffeine and paraxanthine concentration profiles
before and after a 1.5 mg/kg dose of MDMA are
shown in Figure 1, pharmacokinetic parameters
are shown in table 1 and, caffeine urinary MR's
are shown in table 2. Although there were
significant differences in caffeine Cmax following
MDMA (p = 0.025; t = 2.515), no other
differences were found in caffeine and
paraxathine pharmacokinetics between the first
and second session. No correlation was found
between the three MR's and caffeine AUC8h or
17X/137X at 8 h in plasma. There are no
significant differences in the three metabolic
ratios of caffeine and metabolites in urine
between session 1 and session 2.
DISCUSSION
In session 1, caffeine and paraxanthine Cmax
(2345.6 ng/L and 764.7 ng/L) and AUC21h
(11249.6 ng/L.h-1 and 9627.6 jig/L.h-1) values
were similar to previous studies following a dose
of 100 mg[ 19-21]. Caffeine Cmax decreased
significantly from 2345 ng/L to 1883 ng/L (p =
0.025; t = 2.515) following 1.5 mg/Kg MDMA,
however no other pharmacokinetic parameters
differed significantly suggesting that MDMA
does not affect caffeine pharmacokinetics, at
least to the extent that CYP1A2 activity is
affected. This anecdotal observation may be
related to changes in gut pH following MDMA
administration which would affect caffeine
absorption, or indeed a disruption of the active
transport of caffeine by MDMA. A
pharmacokinetic interaction between caffeine
130
Results
and MDMA has been observed[22]. When
MDMA (5 mg/Kg) and caffeine (20 mg/Kg) are
administered together in the rat there is
significant decrease in brain MDMA Cmax and
AUCo-3oomin compared to when MDMA was
administered alone, suggesting an interaction
between the two substances. However, recent
results show that MDMA's transport does not
appear to be P-gp mediated[23]. Another
explanation could come from the fact that both
caffeine and MDMA are known to increase
blood pressure[24;25] and this may affect the
increase of availability of the substrate for first
pass metabolism by an increase in the blood flow
through the hepatic portal vein. However, these
conclusions are purely speculative and beyond
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FIGURE 1. Mean plasma concentrations of
caffeine and paraxthine before (-o-) and
after (-•-) a 1.5 mg/kg dose of MDMA (n =
15: error bars = S.E.I
TABLE 2. Caffeine and metabolite
urinary metabolite ratios for eight recovery
intervals before (session 1) and after
(session 2) a 1.5 mg/Kg oral dose of MDMA




















Caffeine was chosen as a probe for CYP1A2
following an MDMA administration because
being a compound which is normally present in
just about everyone, it had a high safety index
especially following a single dose of a drug of
abuse. Other probes that can be used for the
evaluation of CYP1A2 in humans are
fluvoxamine and phenacetin. Fluvoxamine in
this case cannot be used due to a possible
pharmacodynamic interaction with MDMA.
Phenacetin is as an analgesic and would not be
suitable for such a study with a drug of abuse
and is no longer commercially available as it was
withdrawn because of its induction of
metahemoglobinemia in some patients. At least
six different urinary MR's of caffeine have been
proposed as probes for in vivo CYP1A2 activity.
Notarianni et al.[26] reported very poor
correlations between most of these ratios in a
study of 237 healthy subjects, and concluded
that, since the ratios clearly do not mark the
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same thing, some may be better than others at
indicating CYP1A2 activity. More recently, the
sensitivity of each ratio to change in the intrinsic
activity of CYP1A2 and of other confounding
variables, such as the activities of CYP2A6,
CYP2E1, xanthine oxidase, NAT2 and changes
in urine flow was further explored [27]. In
support of Notariani et al., it was found that the
ratio (AFMU + IX + 1U)/17U in urine was the
best ratio to use. It also showed that cumulative
urine samples are preferable to spot or slice-of-
time samples. Further simulations endorsed the
view of Fuhr and Rost[28] that the plasma or
saliva ratio of 17X/137X measured at 5 ± 7 h is a
much more robust CYP1A2 marker than any of
the urinary metabolite ratios. Hence in this study,
caffeine and six of its respective metabolites
were analyzed in urine, so as to calculate and
compare many ratios.
MR ratios measuring CYP1A2 activity fell
within the ranges of previous studies[29;30].
Interestingly, none of the ratios from session 1
correlated with caffeine AUC8h in this study
sample. No significant changes were observed in
any urinary caffeine MR's following a single
dose of 1.5 mg/kg MDMA. Considering that no
correlation was found between the urinary
caffeine MR's and caffeine clearance and the
high variance in these parameters, it seems that
caffeine and paraxanthine plasma concentrations
are better markers for CYP1A2 activity, at least
for this sample size.
In any case, although an inhibitive interaction
with CYP1A2 could have been observed here, it
is debatable that any induction could be observed
following the administration of a single dose of
MDMA. The induction of CYP1A2 is usually
observed following multiple doses of a putative
inducer with the CYP1A2 probe being
administered after the inducer has been cleared
from the body [31]. The design of the studied is
therefore limited, although a multiple dose study-
using MDMA would be highly unethical and
currently impossible to conduct.
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MDMA affects the activities of the cytochrome P450 enzymes responsible for its phase I









functional gene copy number
Figure 5.1. Box-plots of A. MDMA Cmax and B. HMMA Cmax following an administration of 1.5
mg/kg MDMA by CYP2D6 functional copy number (lines represent median, boxes represent
the first and third quartile, whiskers represent the range).
5.1.1. MDMA pharmacokinetics
MDMA pharmacokinetics were similar to those previously published following a
similar dose45. It was hoped that pharmacokinetic parameters could be
compared by genotype a posteriori, however the frequency of each alíele found
and the small sample size hindered any possible statistical analysis.
Nonetheless, the frequencies of each genotype within the sample were similar to
those found in a Spanish population179. It is worth commenting that any analysis
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of MDMA pharmacokinetics from a controlled clinical trial according to CYP2D6
genotype would require a very large sample size to capture all possible
genotypes, which considering the difficulty in recruiting subjects for such a study,
would be currently implausible. In an attempt to bypass this inconvenience
subjects were given a score according to functional gene copy number. Thus,
individuals possessing alíeles which cause the complete loss of CYP2D6 activity
were given a score of 1 and those possessing alíeles which cause either partial
or complete activity were given a score of 2. As can be seen in Figure 5.1 MDMA
Cmax tended to be higher in subjects possessing only one copy of a functional
alíele (p = 0.078; z = -1.828). HMMA Cmax was also significantly lower in those in
these individuals (p = 0.040; z = -2.089) according to the Mann-Whitney exact
test. It can also be seen that in these individuals MDMA is the main substance
found in plasma whereas in individuals possessing a copy number of two,
HMMA is the main compound found. This may have consequences for
differences in the individual acute effects following a single dose of the drug,
especially in PM individuals who possess two copies of a non-functional alíele.
Indeed, this difference in pharmacokinetic parameters of MDMA has been
observed previously4. However, from the dextromethorphan data presented here
and data from the previous study, concentrations of MDMA and metabolites
following subsequent doses of MDMA would not differ according to CYP2D6
genotype, nullifying any differences in risk of toxicity. No differences were found
in dextromethorphan and metabolite plasma concentrations according to
CYP2D6 functional copy number.
5.1.2. DEX and metabolite pharmacokinetics
A single recreational dose of MDMA caused a dramatic increase in the systemic
exposure to the model CYP2D6 substrate DEX, with a concomitant decrease in
exposure to its primary metabolite DOR. There is a 10 fold increase in plasma
concentrations of DEX following a recreational dose of MDMA. Indeed, there is
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an accumulation effect seen in the concentrations of DEX and DOR following the
second dose of DEX which can be seen by an increase in expected
concentrations of DEX and DOR at 25 h. A similar increase in DEX plasma
concentrations has been observed following a dose of another CYP2D6 inhibitor,
quinidine141'180. Furthermore, the pharmacokinetics of DEX and its metabolites
are comparable to those for PM in the studies cited above, although multiple
dosing of quinidine is needed to phenocopy EMs to PMs. The mechanisms of
inhibition of both compounds are distinct. MDMA administration results in the
MBI of CYP2D6 which has been observed in vitro2'40, this causes an irreversible
inhibition, the recovery of which is dependent on de novo expression of the
enzyme. These observations, which appear to reflect potent mechanism-based
inhibition of CYP2D6, confirm implications suggested by previous
investigations136.
5.1.3. DEX urinary MR
5.1.3.1. Phenocopying
When considering the results in urine, 67% of the volunteers had MR values in
greater than the antimode for phenotype assignment140, suggesting that following
a single dose of MDMA, individuals are phenocopied to the PM. There was no
distinction in genotype between those who did not phenocopy and those that did.
This result explains the absence of correlations between CYP2D6 genotype and
MDMA acute toxicity in the literature, since following the first dose of MDMA the
difference in phenotype is rendered obsolete. This observation also differs from
previous studies with other CYP2D6 MBI's such as paroxetine138 where none of
the subjects attained an MR greater than the antimode for PM assignment. Since
MDMA and paroxetine have similar K( and kinact
181'182, this difference may be due
to differences in dosing (20 mg for paroxetine and 1.5 rng/kg for MDMA) or due
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to high plasma protein binding of paroxetine which would limit its access to
hepatic tissue.
5.1.3.2. Sample variance and DEX MR as a marker for CYP2D6 activity
The use of urinary MR as a measure for CYP2D6 activity has been debated in
the literature. The use of DEX urinary MR has also been questioned due to
contradictory data attempting to correlate it with DEX and DOR plasma levels183.
This ratio is also sensitive to any changes in the renal clearance of DEX. In this
study, using creatinine as a measure of renal function, no correlation was found
between session 1 urinary MR and urine creatinine concentrations. Additionally,
there was no relationship found between urinary pH and DEX urinary MR as
suggested in previous studies145'146. Nevertheless, since the volunteers in this
study were from a homogeneous sample and their dietary intake was not
significantly variable, differences in renal function and pH values were not
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In vitro studies from Baculovirus expression systems suggest that the O-
demethylation of dextromethorphan is carried out predominantly by CYP2D6,
with minor contributions from CYP2B6, CYP2C9, CYP2C18, CYP2C19, CYP2C9
and CYP3A4147"150. An expression that estimates the total net intrinsic metabolic
clearance by the whole liver (Gluant) from data obtained with recombinant
expressed CYP enzymes is given by the following equation:
CluH, ¡nt ZISEF, x
Vmax, (rftCYP; )x CYP, abundance Y
K„>CYPj J
xMPPGL
Where there are / metabolic pathways for each of j CYPs, rh indicates
recombinant expressed enzyme, Vmax is the maximum rate of metabolism by an
individual CYP, Km is the Michaelis constant, MPPGL is the amount of
microsomal protein per gram of liver and ISEF is a scaling factor that
compensates for any difference in the activity per unit of enzyme between
recombinant systems and hepatic enzymes184. The contribution of each CYP to a
particular pathway can then be calculated as a percentage. For DEX O-
demethylation, it can be seen that when CYP2D6 is inhibited, CYP3A4 and
CYP2C9 are responsible for 55% and 29% of DEX O-demethylation,
respectively (Figure 5.2). It should be noted that according to these data the total
intrinsic clearance would decrease substantially following CYP2D6 inhibition,
and this has been observed here in vivo. CYP3A4 is subject to induction and
inhibition by substances found in the diet185'187 and CYP2C9 activity is
polymorphic. Hence, interindividual differences in these enzyme activities could
explain the variance found in the MR in this study following CYP2D6 inhibition by
MDMA. Indeed, in the time interval following the administration of MDMA the
recovery of DEX in urine and the DEX Cmax tends to be greater in individuals
possessing the PM alíele CYP2C9*3. Both these alíeles have been associated














Figure 5.3. Box-plots of DEX urinary recovery and DEX Cmax in the first eight hours
following administration of 1.5 mg/kg MDMA by CYP2C9 genotype (lines represent median,
boxes the first interquartile, whiskers represent the range).
the small sample size, the statistical power is not great enough to draw solid
conclusions about the contribution of CYP2C9 to in vivo DEX clearance when
CYP2D6 is inhibited.
5.1.3.3. The CYP2D6 turnover half-life
The half-life of inhibition was first estimated by non-linear regression according
to a monoexponential equation. However, this model does not fit the observed
data in this study and underestimates the half-life of inhibition. It is clear from the
log transformed data that the recovery of inhibition displayed biphasic kinetics. A
biphasic model was not considered in previous studies measuring Kdeg of
cytochrome P450 isoenzymes137'138. Liston et al. followed the recovery of
inhibition after discontinuation of paroxetine, fluoxetine and sertraline. In the
case of a known MBI paroxetine181, recovery was only monitored for 7 days and
although no statistical differences were seen between the last study day and
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basal values, the inhibition does not appear to have fully recovered after this
time and assumption of first-order kinetics may be premature. Furthermore, upon
considering the data for fluoxetine it appears that the data better fits a biphasic
model. The biphasic recovery of CYP2D6 activity, as marked by serial
measurement of the DEX/DOR MR, may reflect differences between CYP2D6
turnover rates in the gut and liver or a dominant initial competitive inhibition of
the enzyme followed by a greater impact of MBI. The mean value of CYP2D6
half-life of 94 h that was estimated by the biphasic model is greater than the
value of 51 h previously estimated using paroxetine as an inhibitor138'139.
Although this may reflect differences in the subjects studied, this value is within
the 95% confidence interval of that reported previously. Importantly, large
differences in urinary MR found in both studies hamper the accurate calculation
of an inhibition half-life. Additionally, gender and ethnic differences in hepatic
and gut abundance values and distinct CYP2D6 genotype frequencies may be a
reason for differences in estimation. Indeed, in this sample both alíele
CYP2D6*10 and CYP2D6*17 were found. Not only these alíeles have been
associated with decreased intrinsic clearance of DEX in vitro but alíele
CYP2D6*17 has also been associated with decreased MDMA intrinsic
clearance55'189. Furthermore, it has been observed recently that alíele
CYP2D6*10 has an impact on the DEX MR190. At the very least, the sample in
the present study was all male and came from a more homogenous Spanish
population which could account for a more realistic Kdeg value for this population.
A faster degradation half-life of 50 ± 19 h was also calculated for an isoenzyme
similar to CYP2D6, CYP2E1137. However, CYP2E1 is inducible by ligand
stabilization191 which could cause for the underestimation of the half-life. The




5.1.4. Caffeine as a marker for CYP1A2 activity
Caffeine was chosen as a probe for CYP1A2 following an MDMA administration
because being a compound which is normally present in just about everyone, it
had a high safety index especially following a single dose of a drug of abuse.
Other probes that can be used for the evaluation of CYP1A2 in humans are
fluvoxamine and phenacetin. Fluvoxamine in this case cannot be used due to a
possible pharmacodynamic interaction with MDMA. Phenacetin is as an
analgesic and would not be suitable for such a study with a drug of abuse and
whatsmore, is no longer commercially available as it was withdrawn because of
its induction of metahemoglobinemia in some patients. At least six different
urinary MRs of caffeine have been proposed as probes for in vivo CYP1A2
activity (Table 1.4.1). Notarianni et al.166 reported very poor correlations between
most of these ratios in a study of 237 healthy subjects, and concluded that, since
the ratios clearly do not mark the same thing, some may be better than others at
indicating CYP1A2 activity. More recently, further explored the sensitivity of each
ratio to change in the intrinsic activity of CYP1A2 and of other confounding
variables, such as the activities of CYP2A6, CYP2E1, xanthine oxidase, NAT2
and changes in urine flow192. In support of Notariani et al., it was found that the
ratio (AFMU + 1X + 1U)/17U in urine was the best ratio to use. It also showed
that cumulative urine samples are preferable to spot or slice-of-time samples.
Further simulations endorsed the view of Fuhr and Rost193 that the plasma or
saliva ratio of 17X/137X measured at 5 ± 7 h is a much more robust CYP1A2
marker than any of the urinary metabolite ratios. Hence in this study, caffeine and
six of its respective metabolites were analyzed in urine, so as to calculate and
compare many ratios. Furthermore, the pharmacokinetics of caffeine and
paraxanthine in plasma were monitored.
In session 1, caffeine and paraxanthine Cmax (2345 jig/L and 750 jig/L) and AUC0.
24h (11090 ng/L.h~1 and 9499 jag/L.h"1) values were similar to previous studies
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following a dose of 100 mg194"196. MR ratios measuring CYP1A2 activity also fell
within the ranges of previous studies197'198. Interestingly, none of the ratios from
session 1 correlated with caffeine clearance in this study sample. No significant
changes were observed in either urinary caffeine MR's following a single dose of
1.5 mg/kg MDMA. Considering that no correlation was found between the urinary
caffeine MR's and caffeine clearance and the high variance in these parameters,
it seems that caffeine and paraxanthine plasma clearance are better markers for
CYP1A2 activity, at least for this sample size.
Caffeine Cmax decreased significantly from 2345 |ig/L to 1883 |ig/L (p = 0.025; t =
2.515), no other pharmacokinetic parameters differed significantly suggesting that
MDMA does not affect caffeine pharmacokinetics, at least to the extent that
CYP1A2 activity is affected. This anecdotal observation may be related to
changes ¡n gut pH following MDMA administration which would affect caffeine
absorbance, or indeed a disruption of the active transport of caffeine by MDMA. A
pharmacokinetic interaction between caffeine and MDMA has been observed199.
When MDMA (5 mg/kg) and caffeine (20 mg/kg) are administered together in the
rat there is significant decrease in brain MDMA Cmax and AUC0-3oom¡n compared to
when MDMA was administered alone, suggesting an interaction between the two
substances. However, recent results show that MDMA's transport does not
appear to be P-gp mediated200. Another explanation could come from the fact
that both caffeine and MDMA are known to increase blood pressure60'201 and this
may affect the increase the availability of the substrate for first pass metabolism
by an increase in the blood flow through the hepatic portal vein. However, these
conclusions are purely speculative and beyond the scope of results presented
herein.
In any case, although an inhibitive interaction with CYP1A2 could have been
observed here, it is debatable that any induction could be observed following the
administration of a single dose of MDMA. The induction of CYP1A2 is usually
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observed following multiple doses of a putative inducer with the CYP1A2 probe
being administered after the inducer has been cleared from the body202. The
design of the studied is therefore limited, although a multiple dose study using
MDMA would be highly unethical and currently impossible to conduct.
5.1.5. Clinical implications
Considering the clinical implications for MDMA users, following a single dose of
MDMA a CYP2D6 EM are converted to PM according to DEX phenotyping.
Users are known to on average take more than one pill per session (range 1.8 to
2.9 pills) reaching a maximum of 6-7 pills depending on the type of user , with
doses averaging 70 mg (range 50-100 mg) 18. It has also been documented that
many users binge on ecstasy, and these binges may last several days23. Users
must be warned that the risk of acute toxicity due to these practices is drastically
increased. Indeed, it has been shown in a previous study that the concentrations
of MDMA are significantly increased even when the second dose is taken
twenty-four hours later beyond what is expected from accumulation of
concentration3. Evidence presented here suggests that a second dose of MDMA
taken up to one week later would present higher plasma concentrations and
higher risk of acute toxicity. It can even be suggested that MDMA users who use
the drug on a frequent basis have a permanently compromised CYP2D6 activity.
To date the most important CYP2D6 mechanism-based inhibitors marked for
possible toxic drug interactions are SSRI antidepressants such as paroxetine.
Differences in doses taken and the way in which the drugs are administered
have repercussions for their respective toxicities. Paroxetine for instance is a
well studied, prescribed commercial drug and continuing medical education in
psychiatry has increased awareness by prescribers of the potential for drug-drug
interactions203. MDMA is an illegal substance taken at higher but inexact doses
outside the scope of medical supervision. A single recreational dose of MDMA
182
Discussion
rapidly and completely inhibits CYP2D6 whereas several prescription doses of
paroxetine are needed to achieve a similar inhibition46'138.
It is known that MDMA users are not exclusive users of the drug and belong to a
poly-drug abusing population, Dextromethorphan itself is abused at much higher
doses than those given in this study204 and its abuse in combination with MDMA
would cause a toxic interaction. Any other substituted amphetamine that is a
substrate of CYP2D6 would also potentially interact with MDMA in this manner.
Other possible interactions would be with SSRI previously mentioned or other
substrates of CYP2D6 such as codeine, tramadol, risperidone and metoprolol
among others. However, the only fatal interaction reported to date has been with
the antiretroviral and CYP3A4 substrate ritonavir57. On a pharmacodynamic
level, SSRI's such as citalopram and paroxetine block the positive effects of
MDMA69'205. Indeed it has been suggested that MDMA users may take common
SSRI's to modify the effects of MDMA113. It should be noted however that while
the neuropharmacodynamic effects of the drug would be changed, individuals
using SSRI's in conjunction with multiple doses of MDMA may not be aware that
the metabolism of both substances is compromised leading to possible increase
of the risk of acute adverse effects already reported for CYP2D6 PM206. Similar
pharmacodynamic interactions may occur with any abused substance, such as
cocaine and cannabis, even if its metabolism does not have an important
CYP2D6 component. Disproportionately increased MDMA plasma
concentrations in combination with any similar monoaminergic drug would
elevate the risk of toxic episodes associated with the effects of all these drugs of
abuse.
In the context of the general population, the rate of degradation of CYP2D6 and
other cytochrome P450 enzymes of high clinical importance is of relevance since
the knowledge of substrate affinities and/or inhibition and inactivation constants
is not sufficient to accurately predict the pharmacokinetics of potentially new
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drugs at the preclinical level. The half-lives of CYPs calculated can be used
along with intrinsic clearance values, chemical properties and physiological
values from a population to create an in vivo-in vitro extrapolation of the
pharmacokinetics of novel drugs before they are assayed in an animal or
human184. This results in faster and more cost effective drug discovery especially
in the high-throughput pharmaceutical industry of today.
5.2. Animal Studies I
Hypothesis II
Interindividual differences in the activity of catechol-o-methyltransferase (COMT) are
relevant in the development of long-term toxicity of the drug.
5.2.1. COMT inhibition by entacapone in rats
In an attempt to further investigate the role of the catechol type metabolites of
MDMA in the neurotoxic process, entacapone was administered 30 min before
the binge dosing regimen of MDMA. Entacapone is a COMT inhibitor, approved
for human use in the treatment of Parkinsons disease. In this case it acts by
increasing L-dopa availability through its inhibition of its metabolism. The action
of entacapone is mainly thought to be in the periphery, at least in animal models
at doses of up to 10 mg/kg. At higher doses (30 - 100 mg/kg) central COMT
activity is seen to decrease and truly "peripherally selective" inhibition seems to
between doses of 2.5 and 5 mg/kg. However, entacapone does not modify the
effects of clorgylline, selegiline and nomifensine on striatal dopamine metabolism
in the rat brain207. Here, entacapone was administered at 30 mg/kg i.p. and was
chosen based on previous findings indicating that rat liver COMT activity is
completely inhibited 30 min after injection and remains reasonably inhibited
(-75%) six hours later169. It was speculated that this dose would be sufficient to
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inhibit the peripheral metabolism of HHMA and HHA regulated by COMT to
HMMA and HMA respectively and would increase their plasma concentration
and this would, in turn, lead to larger 5-HT depletions. Indeed, entacapone did
exacerbated MDMA-induced long-term 5-HT depletions. In a recent report by
Breier et al.100, it has been suggested that increased tyrosine concentrations
after MDMA and its eventual conversion to DA within 5-HT terminals could play
an important role in MDMA neurotoxicity. According to previously mentioned
data, at the dose used here (30 mg/kg) entacapone will necessarily interfere with
DA turnover and by reducing its metabolism by this pathway, and could enhance
its accumulation or metabolism via other pathways, leading to ROS production
that could enhance 5-HT neurotoxicity. According to results, however, this
possibility seems unlikely since perfusion of entacapone into the hippocampus
did not affect 5-HT or 5-HIAÂ depletions caused by MDMA. Furthermore,
entacapone when given systemically caused no change in serum tyrosine
concentrations. Taken together, these results suggest that entacapone
exacerbates MDMA-induced 5-HT depletions by interfering with peripheral
MDMA metabolism.
Noteworthy, plasma concentrations of HMMA and HMA were significantly lower
in the entacapone treated animals indicating that the O-methylation pathway was
successfully inhibited. By contrast, plasma concentrations of HHMA and HHA
were unchanged suggesting that these compounds must have been cleared
someway. As stated above, HHMA and HHA are highly unstable catechols which
cannot only conjugate with sulphate or glucuronic acid, but can also be rapidly
oxidized to their corresponding orthoquinones and form adducts with GSH and
other thiol-containing compounds5'41'116. Such compounds have been related to
MDMA neurotoxicity11'35'208'209. So, what at first sight was an unexpected finding




The effect of entacapone was not related to an effect on core temperature, since
pre-treatment with entacapone caused a marked hypothermia when injected
alone and did not significantly modify MDMA-induced hyperthermia. Studies in
vitro have been shown that entacapone is a potential uncoupling agent but not at
the doses given here210. However, entacapone co-administration (400 mg/kg)
with L-dopa and carbidopa in rats produced a marked hypothermia similar to that
observed here210. Interestingly, dopamine agonists are known to induce a
decrease in body temperature. The decrease in body temperature seen here
could be due to the increase in dopamine concentrations following COMT
inhibition. If this is the case, then the further increase in dopamine following
MDMA administration should lead to an exacerbated hypothermie response.
Indeed, the opposite is the case, leading to the speculation that it may be the
MDMA-induced hyperthermic response may indeed be 5-HT mediated and not
DA mediated as some studies would suggest79.
5.2.2. Clinical implications
According to these data COMT activity plays an important role in MDMA
metabolism and toxicity in rats. It is known that the level of COMT enzyme
activity is genetically polymorphic in human tissues with a trimodal distribution of
low (COMTLL), intermediate (COMTLH), and high (COMTHH) activities and is
caused by a mutation in position 108/158 of the COMT gene leading to a
Val—»Met substitution. This polymorphism, which according to segregation
analysis of family studies is caused by autosomal co-dominant alíeles, leads to
3- to 4-fold differences in COMT activity in human erythrocytes and liver207. This
in theory would lead to interindividual differences in the concentrations of the
reactive catechol metabolites, HHMA and HHA and could therefore be relevant
for human users in terms of susceptibility to MDMA neurotoxicity. Indeed, after
analysing the pharmacokinetic data for MDMA and HMMA it was found that the
ratio of MDMA to HMMA has a tendency to be higher in val/val individuals
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(Figure 5,4). In otherwords, upon correcting for interindividual differences in
MDMA concentrations (taking the ratio MDMA/HMMA) due to variance in CYP
activity, it can be inferred that subjects possessing the val/val genotype






MDMA systemic metabolism and not MDMA-induced hyperthermia is the limiting step in
the development of long-term neurotoxicity.
5.2.3. MDMA-induced hyperthermia and metabolism
The acute hyperthermia induced by MDMA can strongly influence its long-term
neurotoxic effects76. The blockade of the acute hyperthermic effect of MDMA is a
feature common to many different pharmacological or non-pharmacological
manipulations known to protect against MDMA-induced neurotoxicity and such
protection is abolished when the temperature of the animals is kept
met/met val/met
COMT val/met
val/val me t/met val/met
COMT val/met
val/val
Figure 5.4. Box Plots of the ratios of urinary and plasma concentrations (AUC0-24h) of
MDMA to HMMA versus COMT val/met genotype in humans following a single oral dose of




elevated102'103. Conversely, the degree of long-term damage produced by MDMA
appears to be closely related to the magnitude of the hyperthermic response6.
Furthermore, Cápela et al have demonstrated in vitro that neuronal cell death
caused by MDMA and its metabolites is potentiated at higher temperatures211.
Indeed, generally the production of ROS is increased during hyperthermia114'115.
The quinone thioether conjugates of MDMA metabolites, by redox cycle
interference, are postulated to generate the ROS which leads to neurotoxicity212.
The hyperthermia caused by MDMA may increase ROS production even further
and so lead to the serotonergic changes observed in animals. On the other
hand, hyperthermia may not be a defining factor in MDMA-induced neurotoxicity.
The free radical trapping agent, a-phenyl-A/-tertbutyl nitrone and the serotonin
uptake inhibitor fluoxetine, partially prevent MDMA-induced serotonergic
changes without modifying hyperthermia112'113. The mechanism underlying the
relationship between MDMA-induced changes in core body temperature and
long-term toxicity is as yet unclear. The results show here that MDMA
metabolism is greatly affected by core body temperature, providing new clues to
clarify the relationship between changes in core body temperature and 5-HT
toxicity induced by MDMA.
5.2.3.1. Single dose of MDMA at different temperatures in rats
In the first set of experiments a single high dose of MDMA (15 mg/kg i.p.) was
administered at two different ambient temperatures and the plasma
concentrations of MDMA and its metabolites, MDA, HMMA and HMA were
analyzed for every hour for a period of six hours. The administration of MDMA at
a low ambient temperature (15 ± 1°C) prevented MDMA-induced hyperthermia
and resulted in an almost complete protection. The only region where decreases
in 5-HT and 5-HIAA were detected was in the hippocampus and the percentage
decrease from the saline control was much less than the change at 21°C.
Indeed, this result is not surprising since the hippocampus appears to be more
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sensitive to MDMA-induced neurotoxicity than the striatum or the frontal cortex.
Although consistently reported111'213, the reasons for such different sensitivity are
still unknown. Interestingly, it was also found that hepatic metabolism of MDMA
was reduced. MDMA concentrations were higher than those obtained from rats
treated at a standard ambient temperature (21.5 ± 1°C). Accordingly, plasma
concentrations of MDA, HMMA and HMA in rats treated at 15°C were
significantly lower than those found in rats treated at 21.5°C. Because increases
in ambient temperature exacerbate MDMA-induced 5-HT neurotoxicity and
hyperthermia in the rat6, we also tried to verify whether increasing the ambient
temperature up to 30°C would have consequences on the metabolism of MDMA.
However, we could not successfully carry out these experiments because, under
such experimental conditions, the mortality rate of the animals was above 90%.
5.2.3.2. Multiple doses of MDMA at different temperatures in rats: a model
of "hinging"
One of the main objections often raised to MDMA studies is that the doses of
MDMA used to cause 5-HT toxicity in laboratory animals are too high and do not
resemble those taken by humans. A practice sometimes employed by
recreational ecstasy users is binge dosing, comprising the ingestion of several
doses on a single occasion19. A multiple dosing regimen was administered to
examine how such a regimen influences the effect of MDMA on acute
hyperthermia and long-term 5-HT toxicity. The results indicate that for the same
dose exposure, binge dosing produces an identical acute hyperthermic response
and modification of secondary biomarkers of 5-HT neurotoxicity than a similar
non-divided dose. An interesting finding was that a single high dose of MDMA
(15 mg/kg) resulted in an approximately 20% mortality, while the binge dosing
regimen caused no deaths. Data from others (Bagdy et al. personal
communication) show that the mortality rate after a single high dose of MDMA
(15 mg/kg) increases up to 50-60% in male Dark Agouti rats, an effect that is
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almost completely prevented with a repeated dose regimen of MDMA ( 3 x 5
mg/kg ¡.p., every 2 h). It is interesting to note that the mortality rate is higher in
the former strain than in the Wistar rat, considering that past studies have used
the female Dark Agouti rat as a model for CYP2D6 PM and found that the
hyperthermic response in was higher females than males85.
Subsequently, the first set of experiments was reproduced but by administering a
binge dosing regimen given at low (15°C), standard (21.5°C) and high (30°C)
ambient temperatures. As in the case of a single high dose of MDMA, low
ambient temperature prevented MDMA-induced acute hyperthermia and long-
term 5-HT toxicity. Although somehow expected, MDMA metabolism was also
reduced at 15°C as plasma MDMA concentrations were significantly higher while
those of MDA, HMMA and HMA were lower than those found in rats treated at
21.5°C. It is apparent from these results that despite higher plasma
concentrations of the serotonergic neurotoxin MDMA at low ambient
temperature, hyperthermia and 5-HT depletions induced by MDMA are reduced.
These observations would be in agreement with the hypothesis that a reduction
in drug metabolism is correlated with reductions of biomarkers of neurotoxicity.
The dose regimen used, for an equal total dose exposure, does not substantially
modify these conclusions. Interestingly, the converse also occurred. The
administration of MDMA ( 3 x 5 mg/kg) at 30°C potentiated hyperthermia and
long-term toxicity, but what is most important, the concentrations of all 3
metabolites of MDMA increased drastically over the 6 h time following the first
MDMA injection. Unfortunately, due to an insufficient amount of sample the
concentrations of the catechol type metabolites of MDMA, HHMA and HHA could
not be measured. However, because the only metabolic pathway leading to
HMMA or HMA formation involves the methylation of HHMA and HHA214, it
appears reasonable to suggest that, at some point, the plasma concentrations of
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HHMA and HHA (the proposed precursors of neurotoxic species) must have
been higher in rats treated at 30°C vs. 21 °C.
5.2.3.3. Perfusion of MDMA into the brain of rats
Data from the perfusion experiments confirm and expand on those reported by
others indicating that direct perfusion of MDMA into the brain does not elicit any
sign of 5-HT toxicity119. However, the absence of tissue depletions following the
local infusion of MDMA has been suggested to be due to the lack of effect on
body temperature170. In order to bypass this inconvenience, intrastriatal perfusion
of MDMA (100 ^M, 5h) was combined with MDMA ( 3 x 5 mg/kg i.p.) known to
increase core body temperature. It should be noted that the concentration of
MDMA used in these experiments produces an increase in extracellular DA
concentrations similar to that seen after a toxic MDMA dosing regimen170'215.
Furthermore, such a concentration of MDMA in the perfusate gives rise to the
range of extracellular concentrations of MDMA observed following peripheral
administration of neurotoxic doses of MDMA119. Despite these considerations,
the extent of 5-HT and 5-HIAA depletions was similar and independent of
whatever was perfused seven days earlier. Again, these data are consistent with
the hypothesis that peripheral generation of neurotoxic metabolites contributes to
MDMA-induced serotonergic neurotoxicity.
5.2.3.4. Clinical implications
The data suggest that peripheral metabolism of MDMA plays a key role in the
whole neurotoxic process. Based on the literature and the results presented
herein, it is tempting to speculate that the so far unclear relationship between the
acute hyperthermic response and long-term damage produced by MDMA may
involve the influence of core body temperature in the metabolic rate of this drug.
I should also be pointed out that these findings may be relevant not only for
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future animal investigations, but also for recreational MDMA users in spite of the
limitations of translating animal data to humans216'217. High doses (and or plasma
concentrations) of MDMA are associated with acute toxicity and mortality as it
has also been observed in humans84. The practice of taking low doses of MDMA
repeatedly in a short period of time and for the same dose exposure (i.e. a high
dose inducing acute toxicity and mortality) might reduce the risk of acute toxicity
but does not modify the risk of neurotoxic effects, especially in crowded and hot
dance club conditions where MDMA is often ingested.
5.3. Animal Studies III
Hypothesis IV
MDMA peripheral metabolism and not the formation of free radicals from
tyrosine/dopamine is the limiting step in the development of long-term serotonergic
changes.
5.3.1. The role of L-tyrosine in the development of MDMA-induced
neurotoxicity in rats
The contribution of L-tyrosine or MDMA metabolism to the mechanisms
underlying MDMA-induced brain 5-HT depletions was investigated. For this, a
non-toxic dose of MDMA (7.5 mg/kg i.p.) alone or in combination with L-tyrosine
was first administered. Secondly, using the same dosage regimen of MDMA,
MDMA metabolic disposition was interfered with. Data suggest that while L-
tyrosine can contribute to 5-HT toxicity, MDMA metabolism appears to be the
limiting step in the neurotoxic process.
There is a sizeable amount of evidence indicating that increased free radical
formation is responsible for MDMA-induced neurotoxicity. However, the source
of free radicals responsible for toxicity has been an issue of an intense debate
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during the last two decades. Following on from the experiments in hyperthermic
response, it was decided to focus on the role of peripheral MDMA metabolism
and L-tyrosine.
Since direct injection of MDMA into the brain fails to reproduce the serotonergic
neurotoxicity seen following systemic administration119'170, the first hypothesis
postulates that peripheral metabolism of MDMA into toxic compounds is
responsible for neurotoxicity. In rats, MDMA is mainly N-demethylated by several
cytochrome P450 isozymes to form MDA. MDMA and MDA are further O-
demethylenated to HHMA and HHA, respectively. HHMA and HHA are highly
redox-unstable catechols and can be rapidly oxidized to their corresponding
orthoquinones forming adducts with GSH and other thiol-containing
compounds116. It has been postulated that thioether adducts of MDMA
metabolites cross the blood-brain barrier using glutathione specific
transporters209, and once inside the brain they generate reactive oxygen species
in a 5-HT transporter-dependent manner97'212. Interestingly,
intracerebroventricular administrations of GSH and N-acetylcysteine conjugates
of MDMA metabolites resemble not only the acute neurobehavioral effects of this
drug but also its neurotoxic pattern35. The in vivo detection of quinone thioeter
adducts in rats after MDMA administration and the evaluation of the neurotoxicity
of some of these metabolic species, further strengthens the hypothesis that
MDMA metabolic disposition contributes significantly to the induction of
neurotoxicity11.
On the other hand, a broad amount of evidence appears to indicate that reactive
oxygen species generation responsible for 5-HT depletion is dependent upon the
prolonged and excessive release of DA elicited by MDMA8. It is known that DA
can enter the 5-HT terminal by means of the 5-HT transporter96"98 and once
inside the 5-HT terminal, be deaminated by MAO-B resulting in an elevated
¡ntracellular level of hydrogen peroxide that is reduced by iron to produce
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hydroxyl radicals and a subsequent terminal degeneration8'96'99. Explaining why
MDMA-induced 5-HT depletions also occur in regions such as the hippocampus
or frontal cortex, which are sparsely innervated by DA, is the main drawback of
this hypothesis. This important issue has been expanded upon recently100.
These authors showed that MDMA increases the concentrations of tyrosine in
the brain to cause a long-term depletion of 5-HT via the nonenzymatic, tyrosine
hydroxylase-independent hydroxylation of tyrosine to DOPA and subsequently to
DA via amino acid decarboxylase. However, this latter hypothesis assumes the
pre-existence of hydroxyl free radicals responsible for the oxidation of tyrosine to
DOPA.
5.3.1.1. MDMA metabolism and L-tyrosine plasma concentrations in rats
following a toxic and non-toxic dose
In order to investigate these two hypotheses further, the differences in acute
hyperthermia, L-tyrosine concentrations and MDMA metabolic disposition
between a toxic versus a non-toxic dose of MDMA were analyzed to determine
which, if any, of these parameters could account for differences in long-term
toxicity. Although somewhat expected, plasma concentrations of MDMA and its
main metabolites (MDA, HMMA, HMA) were significantly lower after the non-
toxic versus the toxic dose of MDMA.
Increments in core body temperature and serum tyrosine concentrations were
also significantly lower in rats treated with the low dose of MDMA despite
significance when compared to saline-treated rats. Although hyperthermia
caused by MDMA is a rather complex phenomenon, it is worth noting that the
time course of sustained temperature elevation parallels the sustained elevation
of plasma concentrations of MDA suggesting an important role for MDA in
mediating MDMA-induced hyperthermia. To determine whether the rise in serum
tyrosine concentrations after the low dose of MDMA was insufficient to cause
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toxicity, a non-toxic dose of MDMA (7.5 mg/kg i.p.) in combination with different
doses of L-tyrosine was administered. The combination of MDMA (7.5 mg/kg
¡.p.) and L-tyrosine (0.2 mmol/kg i.p.) yielded similar serum tyrosine
concentrations to those found after the toxic dose of MDMA (15 mg/kg i.p.),
however, this was not enough to cause long-term 5-HT depletions. It was
necessary to increase the dose of L-tyrosine to 0.5 (mmol/kg i.p.) to find
reductions of biomarkers of neurotoxicity. Under these experimental conditions
the ADC of serum L-tyrosine concentrations were higher (~1.7 fold) than those
found after the toxic dose of MDMA. Noteworthy, an excellent correlation has
been demonstrated between serum tyrosine concentrations and brain tissues or
brain microdyalisates following systemic tyrosine administration in the range of
doses used in the present study176. Accordingly, these findings already suggest
that L-tyrosine alone is not enough to explain MDMA-induced 5-HT depletions as
we initially supposed.
5.3.1.2. Perfusion of MDMA into the Striatum in combination with L-tyrosine
The next step was therefore, to interfere with MDMA metabolic disposition.
Previous data indicated that there is a direct relationship between the rise in core
body temperature induced by MDMA and its metabolism. Accordingly, a non-
toxic dose of MDMA (7.5 mg/kg i.p.) in combination with L-tyrosine (0.5 mmol/kg
i.p.) at a low ambient temperature (15 ± 1°C) was administered. Lowering
ambient temperature prevented MDMA-induced hyperthermia and resulted in a
complete protection against 5-HT depletions. To demonstrate that the lack of
toxicity was due to a reduction of MDMA metabolism and not to the lack of
hyperthermia, an experiment in which MDMA was directly perfused into the
striatum in combination with a systemic injection of L-tyrosine (0.5 mmol/kg i.p.)
was performed. Core body temperature of these animals was kept around
39.5°C for 8 h by means of heating pads. It is worth noting that rats stay
hyperthermic for no longer than 6 h when treated with a neurotoxic dose of
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MDMA (15 mg/kg i.p.). It should also be noted that the dose of MDMA used in
these experiments produces an increase in extracellular DA concentrations
similar to that seen after a toxic MDMA dosing regimen170'215. Furthermore, such
concentration of MDMA in the perfusate gives rise to the range of extracellular
concentrations of MDMA observed following peripheral administration of
neurotoxic doses of MDMA119. Despite hyperthermia, large amounts of
extracellular MDMA and of L-tyrosine no significant reduction of striatal ¡ndole
content was observed 7 days later. The contralateral striata, hippocampi and
frontal cortices were also analyzed for 5-HT and 5-HIAA concentrations but no
evidence of 5-HT depletion was found either. Although, hyperthermia is neither
necessary nor sufficient to cause MDMA serotonergic neurotoxicity, it can
strongly influence not only its long-term neurotoxic effects76, but also MDMA
metabolism. Accordingly, a non-toxic dose of MDMA (7.5 mg/kg i.p.) was
administered and once core body temperature began to return to basal levels (2
h later), the heating pads were turned on to maintain rats hyperthermic for 8 h. It
should be noted that by this time (2 h after MDMA), plasma L-tyrosine
concentrations had returned to basal values. Interestingly, these animals showed
significant reductions of 5-HT and 5-HIAA concentrations in all the brain regions
examined 7 days later.
5.3.1.3. COMT inhibition and L-tyrosine
A further experiment was performed with entacapone to investigate if COMT
inhibition would have the same effect as keeping rats hyperthermic in terms of
long-term 5-HT depletions. Noteworthy, the entacapone/MDMA combination
decreased 5-HT concentrations, an effect not related to changes on core body
temperature, since entacapone caused a marked hypothermia when injected
alone but did not significantly alter MDMA-induced hyperthermia. Furthermore,
MDMA increased serum L-tyrosine levels to a higher degree than the
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entacapone/MDMA combination suggesting that MDMA catechol metabolites
and not tyrosine per se, instigate neurotoxicity.
5.3.1.4. Clinical Implications
Although the tyrosine/dopamine hypothesis cannot be ruled out from the
mechanisms underlying MDMA-induced toxicity, especially when the doses of
MDMA are high enough to make tyrosine levels rise sufficiently100, findings
appear to indicate that peripheral metabolism of MDMA may be the limiting step
in the chain of biochemical events leading to 5-HT neurotoxicity.
5.4. General Discussion
It is necessary to make a few comments on the aspects of each experiment and
the limitations that they present. The first question that presents itself is why
certain studies were performed in humans and others in rats. With relation to the
duration of inhibition of CYP2D6, the recovery of enzyme activity is based on de
novo expression of the enzyme and hence studies must be performed in vivo.
Studies have been performed in animals to estimate the turnover rate of
cytochrome P450's but usually differences in values arise when similar studies
are performed in humans137. Furthermore, in the case of CYP2D6 studies in
rodents would be misleading since they do not possess this isozyme. Obviously,
ethical questions come to mind when a clinical trial with a drug of abuse is
performed and the design of the trial and the relatively strict criteria of inclusion
attempt to assuage such matters. In this case, DEX and caffeine were
administered 4 hours following the dose of MDMA to avoid any possible adverse
reactions but at the same time to assure that CYP2D6 inhibition is optimal. At this
time, MDMA peak effects have passed and the substance is entering the
elimination phase of metabolism, so any possible pharmacodynamic interaction
or synergy is avoided. Furthermore, a single recreational dose of MDMA (1.5
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mg/kg) has not caused any serious adverse reactions in a controlled setting to
this date. The sample size of the study is also kept minimal, but, however this
presents limitations when analysing for the impact of certain infrequent CYP2D6
alíeles, such as CYP2D6*10 and CYP2D6*17, and when considering the
variance in the MR's of both DEX and caffeine seen here. Nevertheless, and at
least in the case of DEX MR, the fold change in MR is so drastic that it allows for
a reasonable calculation of CYP2D6 degradation half-life in this sample.
Furthermore, results from caffeine MR's are strengthened by observations in
caffeine and paraxanthine concentrations in plasma. An alternative design to
calculate the duration of inhibition is possible and has been used in the past218.
This design consists of a calculation on the basis of change in AUC over time
rather than urinary MR. However, the design is more invasive on account of the
increase in the amount of blood to withdraw and in the case of CYP2D6 and
dextromethorphan the same limits such as variance in genotype and renal
clearance would apply.
On the other hand studies involving changes in temperature and the inhibition of
the clearance of a putative neurotoxic catechol metabolite of MDMA by
entacapone cannot be performed in humans. Indeed, a clinical trial protocol was
presented for review to the ethical committee of the Hospital del Mar, Barcelona
involving the interaction of the COMT inhibitor, entacapone with MDMA
(IMIMFTCL/MDMA/7). Unfortunately, the protocol was not approved [by
Americans, not by Spaniards] and hence similar studies were performed in an
animal model. However, experiments in animal models involving MDMA present
certain difficulties, especially when interpreting results and applying them to the
clinical consequences for humans. MDMA metabolism of humans and rodents
differs significantly. In rats, the main pathway is N-demethylation to MDA
whereas in humans this pathway is minor, with approximately 5% of the dose
being cleared as MDA. In contrast, the main pathway in humans is O-
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demethylenation to HHMA and subsequent methylation by COMT to HMMA. This
difference could have consequences for the development of long-term
serotonergic changes in both species. However, on a qualitative level it has been
observed here that the inhibition of COMT and temperature changes results in
changes in metabolism in the rat which leads to differences in markers of
neurotoxicity and this alone can be applied to what occurs in MDMA users.
A further question is dose equivalency. Ecstasy is taken orally, but in the animal
studies performed here MDMA was administered intraperitoneally. This would
have obvious consequences for the absorbance kinetics of the drug which may
lead to suggestions of incomparability of results. Furthermore, whether the so
called neurotoxic dose regimen used is comparable to what is taken in humans is
debatable. Many authors argue that the doses are equivalent following
interspecies scaling calculations. However, others argue that calculations of dose
equivalency should be based on the minimal dose which causes a
pharmacological effect. In the case of animal models, doses as little as 1-2 mg/kg
cause distinct behavioural effects126, yet no long-term serotonergic changes have
been observed as these doses. On the other hand, data suggest here that on a
qualitative level MDMA metabolism and the enzymes involved therein have






The general hypothesis of this thesis is that MDMA metabolic disposition
contributes to both acute toxicological effects and mid/long-term
neurotoxicity. Studies evaluating the mechanism based inhibition of MDMA
metabolism and its implication in acute toxicity have been performed in
humans. Studies examining the contribution of COMT (phase II MDMA
metabolic pathway), tyrosine (related to dopamine) and ambient
temperature to neurotoxicity, for ethical reasons have been performed in
animal models.
Conclusion I
This conclusion is related to the hypothesis that MDMA affects the activities of the
cyîochrome P450 enzymes responsible for its phase I metabolism and this has
consequences for the acute and long-term toxicities of the drug.
Key results
• Following a single recreational dose of MDMA, the systemic exposure to the
model CYP2D6 substrate dextromethorphan increases, with a concomitant
decrease in exposure to its primary metabolite dextrorphan.
• The urinary dextromethorphan MR increased drastically, with the majority of
subjects having a value greater than the antimode for assigning the PM
phenotype.
• The MR takes more than ten days to recover to basal values. Using MR to
model the recovery of inhibition a CYP2D6 degradation half-life of 46 h was
calculated.
• A single recreational dose of MDMA does not appear to significantly alter the




There ¡s rapid phenocopymg from the EM phenotype of subjects to apparent PM
status after a single recreational dose of MDMA, explaining the inability to relate
acute toxicity with CYP2D6 genotype.
There are toxicological implications for potent and prolonged inhibition of the
metabolism of other CYP2D6 substrates that might be taken after a single dose
of MDMA (including SSRI's, other amphetamines and DEX itself, which is also
subject to abuse), and for understanding of the determinants of MDMA kinetics
on continuous dose. MDMA users must be warned that the risk of acute
toxicity due to "hinging" on ecstasy is drastically increased. Evidence
suggests that subsequent doses of MDMA taken up to one week later would
present higher plasma concentrations and higher risk of acute toxicity. It can
even be suggested that MDMA users exposed to the drug on a frequent
basis have a permanently compromised CYP2D6 activity.
Conclusion II
This conclusion is related to the hypothesis that interindividual differences in the activity
of catechol-O-tnethyltransferase (COMT) are relevant in the development of long-term
toxicity of the drug.
Key results
• Inhibition of COMT activity in the rat by entacapone given before a neurotoxic
dose regimen of MDMA resulted in a significant reduction of plasma
concentrations of the downstream metabolic products of reactive catechols
implicated in serotonergic changes.
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• COMT inhibition exacerbated the long-term effects of MDMA on rat Índole
content measured in the frontal cortex, hippocampus and striatum 1 week
after drug treatment.
Conclusions
The activity of COMT plays a key role in MDMA metabolic disposition and the
development of serotonergic neurotoxicity caused by the drug in rats.
The COMT polymorphism in humans, which according to segregation analysis of
family studies is caused by autosomal co-dominant alíeles, leads to 3- to 4-fold
differences in COMT activity in the liver and could therefore be relevant for
human users in terms of susceptibility to MDMA neurotoxicity.
Conclusion HI
This conclusion pertains to the hypothesis that it is MDMA systemic metabolism and not
MDMA-induced hyperthermia that is the limiting step in the development of long-term
neurotoxicity.
Key results
• The administration of single and multiple doses ("binging" or "stacking"
regimen) of MDMA at 15°C blocked the hyperthermic response and long-term
5-HT depletion found in rats treated at 21.5°C. At 15°C, plasma
concentrations of MDMA were significantly increased while those of three of
its main metabolites were reduced when compared to rats treated at 21.5°C.




• Perfusion of MDMA into the striatum did not alter the core body temperature
of rats. Acute hyperthermia and long-term loss of 5-HT and 5-HIAA content in
the striatum were evident only when MDMA was given systemically.
• The effect of entacapone on 5-HT depletions caused by MDMA was
independent of any effect of MDMA-induced hyperthermia.
Conclusions
Data suggest that peripheral metabolism of MDMA plays a key role in the
whole neurotoxic process. It is tempting to speculate that the so far unclear
relationship between the acute hyperthermic response and long-term damage
produced by MDMA may rely on the large influence of core body temperature in
the metabolic rate of this drug.
This finding has implications on both the temperature dependence of the
mechanism of MDMA neurotoxicity and human use, as hyperthermia is often
associated with MDMA use in humans. The practice of "stacking" does not
modify the risk of neurotoxic effects, especially in crowded and hot dance
club conditions where MDMA is often ingested.
Conclusion IV
This conclusion states that although the tyrosine/dopamine neurotoxicity hypothesis
cannot be ruled out, MDMA peripheral metabolism appears to be the limiting step in the
development of long-term serotonergic changes.
Key results
• The administration of a non-toxic dose of MDMA in combination with L-
tyrosine produced no changes in brain 5-HT content while a similar increase
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in serum tyrosine levels to those found after a toxic dose of MDMA was
observed.
• The non-toxic dose of MDMA combined with a higher dose of tyrosine,
caused long-term 5-HT depletions in rats treated at 21.5°C but not in those
treated at 15°C, conditions known to decrease MDMA metabolism.
• Striatal perfusion of MDMA combined with tyrosine in hyperthermic rats did
not cause 5-HT depletions. By contrast, rats treated with the non-toxic
peripheral dose of MDMA under heating conditions or combined with
entacapone or acivicin, which interfere with MDMA metabolism or increase
brain MDMA metabolite availability respectively, showed significant
reductions of brain 5-HT content.
Conclusions
Data suggest that while L-tyrosine can contribute to 5-HT toxicity, MDMA
metabolism appears to be the limiting step in the neurotoxic process,
although the tyrosine/dopamine hypothesis from the mechanisms underlying
MDMA-induced toxicity cannot be ruled out, especially when the doses of MDMA
are high enough to make tyrosine levels increase sufficiently.
General Conclusion
Data suggest that although the hyperthermia and increased dopamine release
caused following MDMA administration may modulate MDMA-induced
neurotoxicity, it is the peripheral metabolism of MDMA, most likely through the
generation of reactive catechol metabolites, that plays a key role in the whole
neurotoxic process. Interindividual differences in CYP2D6 activity and their
correlation with MDMA-induced toxic episodes are rendered insignificant by the
autoinhibition of this enzyme. However, users must be warned of the duration
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and subsequent consequences of such an inhibition. It appears that differences
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DETERMINACIÓN: CUANTIFICACION DE DEXTROMETORFANO, DEXTRORFANO,
METOXIMORFINAN Y MORFINAN-3-OL EN ORINA HUMANO
3-
| CÓDIGO DET.: PNT: LOTE:
A. PREPARACIÓN DE LAS MUESTRAS
GRADILLA, identificar # lote
1 +TUBO: identificar : CI (control inferior) [LOTE: ]
2_+TUBO: identificar : CM (control medio) [LOTE: ]
3 +TUBO: identificar : CS {control superior) [LOTE: ]
4 +TUBO: identificar BLO1 (blanco de reactivo)
5_ + 2.5 mL de H2O MilüQ [DI: ]
6 +TUBO: identificar BLO1 (blanco de orina sin estándar interno)
7 + 2.5 mL de orina blanco*
8 +TUBO: identificar BLO2 (blanco de orina con estándar interno)
9 + 2,5 mL de de orina blanco*
10_+10 TUBOS: identificar:
11 CA11 y CA12: + 2.5 mL orina blanco* + 40 ul de solución 2,5 ug/mL [LOTE:
12 CA21 y CA22: + 2.5 mL orina blanco* + 25 ul de solución 25 ug/mL [LOTE:
13 CA31 y CA32: + 2.5 mL orina blanco* + 50 ul de solución 25 ug/mL [LOTE:
14 CA41 y CA42: + 2.5 mL orina blanco* + 80 ul de solución 25 ug/mL [LOTE:
15 CA51 y CA52: + 2.5 mL orina blanco* + 20 ul de solución 250 ug/mL [LOTE:
16 vórtex 10 seg (a todos los tubos)
][DI: ]
J[DI:
17 Adjuntar los TUBOS necesarios para las muestras e identificarlos con el código correspondiente.
18 + 2.5 mL de la muestra correspondiente en cada tubo [DI: ]
(Las muestras deben estar previamente homogeneizadas con vórtex)
19_+ 20 pi de la solución ISTD (lOO^g/mL) [LOTE:
20 vórtex, 5 seg
] [DI: ] a todos los tubos excepto al tubo BLP1.
21 +1 mL de ß-glucuronidasa HP-1 (10mg/mL) en 0.1 M citrato de sodio pH 5.0 [LOTE:
22 vórtex, 5 seg.; tapar los tubos
23 baño a 37°C durante 16 horas/ baño a 55°C durante 3 horas
24_-H mL de NH4CI/NH3 pH 9 [LOTE: ] [DI: ]
25 vórtex, 5 seg
26 centrifugar 5 minutos a 3500 rpm.
PROCESADOR ESL, identificar # lote
27 _+ COLUMNAS BOND-ELUT CERTIFY [LOTE: ]; identificadas como los tubos
28_+2mLMeOH [LOTE: ][DI: ]
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DETERMINACIÓN: CUANTIFICACION DE DEXTROMETORFANO, DEXTRORFANO, 3-
METOXIMORFINAN Y MORFINAN-3-OL EN ORINA HUMANO
I CÓDIGO PET.: ] | PNT: [ [LOTE:
30 decantar muestra
31 pasar la muestra lentamente
32 __+2 mL H2O MilliQ [ LOTE: ] [ DI: ]
33 __+1 mL CH3COOH 1M [ LOTE: ] [ DI: ]
34 _+2 mL MeOH [LOTE: ][ D1:163 ]
35 secar las columnas 10 min. (presión máxima)
36 + TUBOS DE ELUCIÓN: identificarlos y ponerlos bajo las columnas respectivas
37_+2 mL de CH3CI:PrOH 80:20, NH3 2% [LOTE: ] [DI: ]
(preparación extemporánea)
38 evaporar a sequedad bajo N2 (40°C)
39 reconstruir en 100 ni fase móvil
vórtex, 5 seg
40__CAJA SOPORTE VIALES, identificar: #lote
41 +VIALES EPPENDORF con microvial, identificar como los tubos
42 transferir conten, tubos
43 ultracentrifugación (10000 g), 5 min
CAJA SOPORTE VIALES, identificar # lote
44 + VIALES con microvial, identificar
45 capsular
B. ANÁLISIS INSTRUMENTAL
46 Instrumento: CL/FLD Código instrumento:
Método instrumental:
* BLANCO DE PLASMA: [LOTE: ) [DI: ]
FECHA OPERACIONES NOMBRE FIRMA
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DETERMINACIÓN: CUANTIFICACION DE DEXTROMETORFANO, DEXTRORFANO,
METOXIMORFINAN Y MORFINAN-3-OL EN PLASMA HUMANO
3-
CODIGO DET.: PNT: LOTE:
A. PREPARACIÓN DE LAS MUESTRAS
GRADILLA, identificar # lote
1 -t-TUBO: identificar : Cl (control inferior) [LOTE: ]
2 +TUBO: identificar : CM (control medio) [LOTE: ]
3 +TUBO: identificar : CS (control superior) [LOTE: ]
4 +TUBO: identificar BLR1 (blanco de reactivo)
5_ + 1 mLdeH2OMilliQ [Dl: ]
6 +TUBO: identificar BLP1 (blanco de plasma sin estándar interno)
7 + 1 mL de plasma blanco*
8 +TUBO: identificar BLP2 (blanco de plasma con estándar interno)
9 + 1 mL de de plasma blanco*
10_+10 TUBOS: identificar:
11 CA11 y CA12: + 1 mL plasma blanco* + 40 ul de solución 0.25 ug/mL [LOTE: ][DI:
12 CA21 y CA22: + 1 mL plasma blanco* + 20 ul de solución 2.5 ug/rnL [LOTE: ][DI:
13 CA31 y CA32: + 1 mL plasma blanco* + 40 pl de solución 2.5 ug/mL [LOTE: ][DI:
14 CA41 y CA42: + 1 mL plasma blanco* + 80 ul de solución 2.5 ug/mL [LOTE: ][DI:
15 CA51 y CA52: + 1 mL plasma blanco* + 120 pi de solución 2.5 ug/mL [LOTE: J[DI:
16 vórtex 10 seg (a todos los tubos)
17 Adjuntar los TUBOS necesarios para las muestras e identificarlos con el código correspondiente.
18 + 1 mL de la muestra correspondiente en cada tubo [DI: ]
(Las muestras deben estar previamente homogeneizadas con vórtex)
19_+ 20 pl de la solución ISTD (1 Ong/mL) [LOTE: ] [DI:
20 vórtex, 5 seg
| a todos los tubos excepto al tubo BLP1.
21 +500 ul de ß-glucuronidasa HP-1 (10mg/mL) en 0.1M citrato de sodio pH 5.0 [LOTE:
22 vórtex, 5 seg.; tapar los tubos
24 baño a 37°C durante 16 horas/ baño a 55°C durante 3 horas
25_+500 ul de NH4CI/NH3 pH 9 [LOTE: ] [DI: ]
26 vórtex, 5 seg
27 centrifugar 5 minutos a 3500 rpm.
PROCESADOR ESL, identificar # lote
28 _+ COLUMNAS BOND-ELUT CERTIFY [LOTE: ]; identificadas como los tubos
29 _+2 mL MeOH [ LOTE: ] [ DI: ]
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DETERMINACIÓN: CUANTIFICACION DE DEXTROMETORFANO, DEXTRORFANO, 3-
METOXIMORFINAN Y MORFINAN-3-OL EN PLASMA HUMANO
| CÓDIGO PET.: ] | PNT: | [LOTE:
31 decantar muestra
32 pasar la muestra lentamente
33 _+2 mL H2O MilliQ [ LOTE: ] [ DI: ]
34 __+1 mL CH3COOH 1M [ LOTE: ] [ DI: ]
Secar las columnas 10 sec (presión máxima)
35 _+2 mL MeOH [LOTE: ][ DI: ]
36 secar las columnas 10 min. (presión máxima)
37 + TUBOS DE ELUCIÓN: identificarlos y ponerlos bajo las columnas respectivas
38_+2 mL de CH3CI:PrOH 80:20, NH3 2% [LOTE: ] [DI: ]
(preparación extemporánea)
39 evaporar a sequedad bajo N2 (40°C)
40 reconstruir en 50 ni fase móvil
vórtex, 5 seg
41_ CAJA SOPORTE VIALES, identificar: #lote
42 +VIALES EPPENDORF con microvial, identificar como los tubos
43 transferir conten, tubos
44 ultracentrifugación (10000 g), 5 min
CAJA SOPORTE VIALES, identificar # lote




46 Instrumento: CL/FLD Código instrumento:
Método instrumental:
* BLANCO DE PLASMA: [LOTE: ] [DI: ]
FECHA OPERACIONES NOMBREFIRMA
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DETERMINACIÓN: CUANTIFICACION DE CAFEÏNA Y METABOLITOS EN ORINA HUMANA
CÓDIGO DET.: | PNT: LOTE:
A. PREPARACIÓN DE LAS MUESTRAS
GRADILLA, identificar # lote
1 +TUBO: identificar : CI (control inferior) [LOTE: ]
2_+TUBO: identificar : CM (control medio) [LOTE: ]
3 +TUBO: identificar : CS (control superior) [LOTE: ]
4 +TUBO: identificar BLR1 (blanco de reactivo)
5_ + 150|ildeH2OMilliQ [DI: ]
6 +TUBO: identificar BLO1 (blanco de orina sin estándar interno)
7 + 150 ni de orina blanco*
8 +TUBO: identificar BLO2 (blanco de orina con estándar interno)
9 + 150 ni de orina blanco*
10 +10 TUBOS: identificar:
11 CA11 y CA12: + 150 ni orina blanco* + 30 ul de solución mix 10 ug/mL [LOTE: ][DI: ]
12_ CA21 y CA22: + 150 ni orina blanco* + 15 ul de solución mix 100 ug/mL [LOTE: ][DI: ]
13 CA31 y CA32: + 150 ni orina blanco* + 30 ul de solución mix 100 ug/mL [LOTE: ][DI: ]
14 CA41 y CA42: + 150 ni orina blanco* + 45 ul de solución mix 100 ug/mL [LOTE: ][DI: ]
15 CA51 y CA52: + 150 ni orina blanco* + 90 ul de solución mix 100 ug/mL [LOTE: ][DI: ]
16 vórtex 10 seg (a todos los tubos)
17 Adjuntar los TUBOS necesarios para las muestras e identificarlos con el código correspondiente.
18 + 150 ni de la muestra correspondiente en cada tubo [DI: ]
(Las muestras deben estar previamente homogeneizadas con vórtex)
19_+ 30 ul NaOH 0.5 M (conversión de AFMU en AAMU) [LOTE: ] [DI: ]
20 vórtex 5 seg, dejar 30 min a temperatura ambiente
21_+ 40 ul HCI 0.5 M (volver a pH de orina) [LOTE: ] [DI: ]
22 vórtex 5 seg
23 +30 M< solución ISTD (9-metil úrico 100ng/mL) [LOTE: ] [DI: ] a todos los tubos excepto al tubo BLO1.
24_vórtex, 5 seg
25_+100 ul DMF/AcOEt (30:70) [LOTE: ] [DI: ]
26 vórtex, 5 seg
27__+800 ul ACN [LOTE: ] [DI: ]
28 vórtex, 30 seg
29_ CAJA SOPORTE VIALES, identificar: #lote
30 +VIALES EPPENDORF con microvial, identificar como los tubos
31 transferir conten, tubos
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| DETERMINACIÓN: CUANTIFICACIÓN DE CAFEÍNA Y METABOLITOS EN ORINA HUMANA





CAJA SOPORTE VIALES, identificar # lote
transferir contenido tubos


















c/ Doctor Aiguader, 80. E-08003 Barcelona. NIF: P-5890004-D. Tel. (+34)93221 1009. Fax (+34) 93221 3237. E-mail: postmaster@imim.e
DETERMINACIÓN: CUANTIFICACIÓN DE CAFEÍNA Y PARAXANTINA EN PLASMA HUMANO
CÓDIGO DEL: | PNT: | LOTE:
A. PREPARACIÓN DE LAS MUESTRAS
GRADILLA, identificar # lote
1 +TUBO: identificar : CI (control inferior) [LOTE: ]
2_+TUBO: identificar : CM (control medio) [LOTE: ]
3 +TUBO: identificar : CS (control superior) [LOTE: ]
4 +TUBO: identificar BLR1 (blanco de reactivo)
5_ + 500 ni de H2O MilliQ [DI: ]
6 +TUBO: identificar BLP1 (blanco de plasma sin estándar interno)
7 + 500 ni de plasma blanco*
8 +TUBO: identificar BLP2 (blanco de plasma con estándar interno)
9 + 500 ni de plasma blanco*
10_+10 TUBOS: Identificar:
11_ CA11 y CA12:+ 500 ni Plasma blanco*+ 5 pide solución 1 [LOTE: ][DI: ]
12_ CA21 y CA22: + 500 ni plasma blanco* + 20 ul de solución 1 [LOTE: ][DI: ]
13_ CA31 y CA32: + 500 ni plasma blanco* + 5 ul de solución 2 [LOTE: ][DI: ]
14_ CA41 y CÂ42: + 500 ni plasma blanco* + 10 ul de solución 2 [LOTE: ][DI: ]
15 CA51 y CA52: + 500 ni plasma blanco* + 20 ul de solución 2 [LOTE: ][DI: ]
16 vórtex 10 seg (a todos los tubos)
17 Adjuntar los TUBOS necesarios para las muestras e identificarlos con el código correspondiente.
18 + 500 ul de la muestra correspondiente en cada tubo [DI: ]
(Las muestras deben estar previamente homogeneizadas con vórtex)
19 30 ul solución ISTD (diphyline 10ng/mL) [LOTE: ] [DI: ] a todos los tubos excepto al tubo BLP1.
20 vórtex, 5 seg
21 + 200 mg sulfato de amoniaco [LOTE: ] [DI: ]
22 vórtex hasta disolución
23_+ 5 mL acetato de etil [LOTE: ] [DI : ]
24 vortex 5 sec
24 agitador basculante 40mov/min, 20 min
25 centrifugar 3500 rpm, 10 min
26__GRADILLA, identificar # lote
27 + TUBOS: Identificadas como los otros
28 transferir fase organ.
29 evaporar bajo N2, 40°C [T: °C]
30_+100 ni 0.05% CH3COOH [LOTE: ] [DI ]
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DETERMINACIÓN: CUANTIFICACIÓN DE CAFEÍNA Y PARAXANTIN A EN
imim.e
PLASMA HUMANO
CÓDIGO DET.: | PNT: LOTE:
32 +VIALES EPPENDORF con microvial, identificar como los tubos
33 transferir conten, tubos
34 ultracentrifugación (10000 g), 5 min
35_ CAJA SOPORTE VIALES, identificar # lote
36 transferir contenido tubos
37 + VIALES con microvial, identificar
38 capsular
B. ANÁLISIS INSTRUMENTAL
46 Instrumento: CLAE/UV Código instrumento:
Método instrumental:
* BLANCO DE PLASMA: [LOTE: ] [DI: ]
FECHA OPERACIONES NOMBREFIRMA
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DETERMINACIÓN: CUANTIFICACiÔN DE MDMA, MDA, HMMA Y HMA EN PLASMA HUMANO
CÓDIGO DEL: 7018 PNT: MF018E01 | LOTE:
A. PREPARACIÓN DE LAS MUESTRAS
GRADILLA, identificar # lote
1 +TUBO: identificar : CI (control inferior) [LOTE: ]
2 +TUBO: identificar : CM (control medio) [LOTE: ]
3 +TUBO: identificar : CS (control superior) [LOTE: ]
4 +TUBO: identificar BLR1 (blanco de reactivo)
5_ + 1 mL de H2O MilHQ [DI: ]
6 +TUBO: identificar BLP1 (blanco de plasma sin estándar interno)
7 + 1 mL de plasma blanco*
8 +TUBO: identificar BLP2 (blanco de plasma con estándar interno)
9 + 1 mL de plasma blanco*
10_+10 TUBOS: identificar:
11_ CA11 y CA12: +1 mL plasma blanco*+ 25 MÍ de solución 1 [LOTE: ][DI: ]
12_ CA21 y CA22: + 1 mL plasma blanco* + 10 ul de solución 2 [LOTE: ][DI: ]
13 CA31 y CA32: + 1 mL plasma blanco* + 20 ul de solución 2 [LOTE: ][DI: ]
14_ CA41 y CA42: + 1 mL plasma blanco* + 30 ul de solución 2 [LOTE: ][DI: ]
15__ CA51 y CA52: + 1 mL plasma blanco* + 40 ul de solución 2 [LOTE: ][DI: ]
16_vórtex 10 seg (a todos los tubos)
17 Adjuntar los TUBOS necesarios para las muestras e identificarlos con el código correspondiente.
18 + 1 mL de la muestra correspondiente en cada tubo [DI: ]
(Las muestras deben estar previamente homogeneizadas con vórtex)
19 + 20 Mi de la solución ISTD [LOTE: ] [DI: ] a todos los tubos excepto al tubo BLP1.
20 vórtex, 5 seg
21_+1 mL de TAS 1M pH=5.2 [LOTE: ] [DI: 1
22_+ 50ul de ß-glucuronidasa HP-2. [LOTE: ] [DI: ]
23 vórtex, 5 seg.; tapar los tubos
24 baño a 37°C durante 16 horas
25_+1mLdeTFP0.1MpH6[LOTE: ] [DI: ]
26__vórtex, 5 seg
27 centrifugar 5 minutos a 3500 rpm.
PROCESADOR ESL, identificar # lote
28 _+ COLUMNAS BOND-ELUT CERTIFY [LOTE: ]; idenmtificadas como los tubos
29_+2mLMeOH [LOTE: ] [ DI: ]
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DETERMINACIÓN: CUANTIFICACIÓN DE MDMA, MDA, HMMA Y HMA EN PLASMA HUMANO
CÓDIGO DEL: 7018 PNT: MF018E01 LOTE:
31 decantar muestra
32 pasar la muestra lentamente
33 _+1 mL de ácido acético 1M [ LOTE: ] [ DI: ]
34 _+6 mL MeOH [LOTE: ][ DI: ]
35 secar las columnas 2 min. (presión máxima)
36 + TUBOS DE ELUCIÓN: identificarlos y ponerlos bajo las columnas respectivas
37_+2 mL de acetato de etilo al 2% NH3 [LOTE: ] [DI: ]
(preparación extemporánea)
38_+20 uL de MBTFA [ LOTE: ] [ DI: ]
39 evaporar a sequedad bajo N2 (40°C)
40 estufa de vacío 1 hora
41_+50 uL de MBTFA [LOTE: ] [ DI: ]
vórtex 10 seg; tapar
42 baño seco a 70 °C durante 45 min
CAJA SOPORTE VIALES, identificar # lote
43 + VIALES con microvial, identificar
44 transferir contenido tubos
45 capsular
B. ANÁLISIS INSTRUMENTAL
46 Instrumento: CG/EM Código instrumento:
Método instrumental:
NOTA: Los viales de limpieza del inyector deben contener acetona.
* BLANCO DE PLASMA: [LOTE: ] [DI: ]
FECHA OPERACIONES NOMBREFIRMA


